AU774651B2 - Reduction of the immunogenicity of non-human grafts - Google Patents
Reduction of the immunogenicity of non-human grafts Download PDFInfo
- Publication number
- AU774651B2 AU774651B2 AU70460/00A AU7046000A AU774651B2 AU 774651 B2 AU774651 B2 AU 774651B2 AU 70460/00 A AU70460/00 A AU 70460/00A AU 7046000 A AU7046000 A AU 7046000A AU 774651 B2 AU774651 B2 AU 774651B2
- Authority
- AU
- Australia
- Prior art keywords
- cells
- tissue
- macrophages
- human
- porcine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000005847 immunogenicity Effects 0.000 title claims description 9
- 230000009467 reduction Effects 0.000 title description 4
- 210000004027 cell Anatomy 0.000 claims description 235
- 210000002540 macrophage Anatomy 0.000 claims description 76
- 230000002025 microglial effect Effects 0.000 claims description 65
- 230000000295 complement effect Effects 0.000 claims description 57
- 210000002966 serum Anatomy 0.000 claims description 48
- 230000001537 neural effect Effects 0.000 claims description 38
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 30
- 239000003153 chemical reaction reagent Substances 0.000 claims description 22
- 238000002054 transplantation Methods 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 18
- 230000001605 fetal effect Effects 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 17
- 238000011282 treatment Methods 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 16
- 102000004190 Enzymes Human genes 0.000 claims description 14
- 108090000790 Enzymes Proteins 0.000 claims description 14
- 229940088598 enzyme Drugs 0.000 claims description 14
- 238000010494 dissociation reaction Methods 0.000 claims description 13
- 230000005593 dissociations Effects 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 11
- 239000006096 absorbing agent Substances 0.000 claims description 8
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 6
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 6
- 208000012902 Nervous system disease Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 102000035195 Peptidases Human genes 0.000 claims description 5
- 108091005804 Peptidases Proteins 0.000 claims description 5
- 239000004365 Protease Substances 0.000 claims description 5
- 229940119679 deoxyribonucleases Drugs 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- 208000025966 Neurological disease Diseases 0.000 claims description 4
- 208000002193 Pain Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 3
- 206010015037 epilepsy Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 230000000779 depleting effect Effects 0.000 claims 2
- 210000004958 brain cell Anatomy 0.000 description 72
- 239000002953 phosphate buffered saline Substances 0.000 description 53
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 52
- 210000001519 tissue Anatomy 0.000 description 49
- 239000002609 medium Substances 0.000 description 41
- FHIVAFMUCKRCQO-UHFFFAOYSA-N diazinon Chemical compound CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 39
- 238000010186 staining Methods 0.000 description 39
- 241000282898 Sus scrofa Species 0.000 description 35
- 210000001744 T-lymphocyte Anatomy 0.000 description 34
- 239000000427 antigen Substances 0.000 description 27
- 108091007433 antigens Proteins 0.000 description 27
- 102000036639 antigens Human genes 0.000 description 27
- 210000001130 astrocyte Anatomy 0.000 description 27
- 238000000684 flow cytometry Methods 0.000 description 25
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 23
- 210000004556 brain Anatomy 0.000 description 23
- 210000004698 lymphocyte Anatomy 0.000 description 22
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 description 21
- 239000012894 fetal calf serum Substances 0.000 description 21
- 239000003656 tris buffered saline Substances 0.000 description 20
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 19
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 210000005013 brain tissue Anatomy 0.000 description 16
- 238000011534 incubation Methods 0.000 description 16
- 210000002889 endothelial cell Anatomy 0.000 description 15
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 14
- 241000700159 Rattus Species 0.000 description 14
- 239000006285 cell suspension Substances 0.000 description 14
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 14
- 101100005713 Homo sapiens CD4 gene Proteins 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 210000002257 embryonic structure Anatomy 0.000 description 12
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 12
- 230000035755 proliferation Effects 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 11
- 210000002569 neuron Anatomy 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 102000053171 Glial Fibrillary Acidic Human genes 0.000 description 10
- 101710193519 Glial fibrillary acidic protein Proteins 0.000 description 10
- 108090001090 Lectins Proteins 0.000 description 10
- 102000004856 Lectins Human genes 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 10
- 210000005046 glial fibrillary acidic protein Anatomy 0.000 description 10
- 238000002955 isolation Methods 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 102000013415 peroxidase activity proteins Human genes 0.000 description 9
- 108040007629 peroxidase activity proteins Proteins 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 230000004083 survival effect Effects 0.000 description 8
- 102100032912 CD44 antigen Human genes 0.000 description 7
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 7
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 7
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 7
- 239000013504 Triton X-100 Substances 0.000 description 7
- 229920004890 Triton X-100 Polymers 0.000 description 7
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 7
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 7
- 238000000386 microscopy Methods 0.000 description 7
- 239000013642 negative control Substances 0.000 description 7
- 230000002062 proliferating effect Effects 0.000 description 7
- 230000009696 proliferative response Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 229930182555 Penicillin Natural products 0.000 description 6
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 6
- 230000000735 allogeneic effect Effects 0.000 description 6
- 239000011324 bead Substances 0.000 description 6
- 210000000601 blood cell Anatomy 0.000 description 6
- 210000005064 dopaminergic neuron Anatomy 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 239000012528 membrane Substances 0.000 description 6
- 229940049954 penicillin Drugs 0.000 description 6
- 239000006228 supernatant Substances 0.000 description 6
- 230000035899 viability Effects 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- 229930182816 L-glutamine Natural products 0.000 description 5
- 230000005867 T cell response Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 210000000170 cell membrane Anatomy 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 210000004748 cultured cell Anatomy 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 210000001259 mesencephalon Anatomy 0.000 description 5
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 229960005322 streptomycin Drugs 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- 102000043129 MHC class I family Human genes 0.000 description 4
- 108091054437 MHC class I family Proteins 0.000 description 4
- 102000043131 MHC class II family Human genes 0.000 description 4
- 108091054438 MHC class II family Proteins 0.000 description 4
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 102000008763 Neurofilament Proteins Human genes 0.000 description 4
- 108010088373 Neurofilament Proteins Proteins 0.000 description 4
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 108010034949 Thyroglobulin Proteins 0.000 description 4
- 102000009843 Thyroglobulin Human genes 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 210000003754 fetus Anatomy 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 210000003061 neural cell Anatomy 0.000 description 4
- 210000005044 neurofilament Anatomy 0.000 description 4
- 230000005298 paramagnetic effect Effects 0.000 description 4
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
- 229940104230 thymidine Drugs 0.000 description 4
- 229960002175 thyroglobulin Drugs 0.000 description 4
- 238000001262 western blot Methods 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 3
- 229930105110 Cyclosporin A Natural products 0.000 description 3
- 108010036949 Cyclosporine Proteins 0.000 description 3
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 239000006145 Eagle's minimal essential medium Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000935040 Homo sapiens Integrin beta-2 Proteins 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 206010062016 Immunosuppression Diseases 0.000 description 3
- 102100025390 Integrin beta-2 Human genes 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 230000006052 T cell proliferation Effects 0.000 description 3
- 239000006180 TBST buffer Substances 0.000 description 3
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000002403 aortic endothelial cell Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000011072 cell harvest Methods 0.000 description 3
- 229960001265 ciclosporin Drugs 0.000 description 3
- 238000003501 co-culture Methods 0.000 description 3
- 229930182912 cyclosporin Natural products 0.000 description 3
- 230000009089 cytolysis Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 210000004002 dopaminergic cell Anatomy 0.000 description 3
- 238000000799 fluorescence microscopy Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 230000001506 immunosuppresive effect Effects 0.000 description 3
- 238000010874 in vitro model Methods 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 230000000873 masking effect Effects 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 3
- 210000004498 neuroglial cell Anatomy 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- DIVDFFZHCJEHGG-UHFFFAOYSA-N oxidopamine Chemical compound NCCC1=CC(O)=C(O)C=C1O DIVDFFZHCJEHGG-UHFFFAOYSA-N 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 230000008782 phagocytosis Effects 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 238000002203 pretreatment Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000009257 reactivity Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 2
- IQFYYKKMVGJFEH-OFKYTIFKSA-N 1-[(2r,4s,5r)-4-hydroxy-5-(tritiooxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1[C@H](O)[C@@H](CO[3H])O[C@H]1N1C(=O)NC(=O)C(C)=C1 IQFYYKKMVGJFEH-OFKYTIFKSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 208000002109 Argyria Diseases 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108090001008 Avidin Proteins 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102000020897 Formins Human genes 0.000 description 2
- 108091022623 Formins Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 102000018697 Membrane Proteins Human genes 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 210000000612 antigen-presenting cell Anatomy 0.000 description 2
- RMRJXGBAOAMLHD-IHFGGWKQSA-N buprenorphine Chemical compound C([C@]12[C@H]3OC=4C(O)=CC=C(C2=4)C[C@@H]2[C@]11CC[C@]3([C@H](C1)[C@](C)(O)C(C)(C)C)OC)CN2CC1CC1 RMRJXGBAOAMLHD-IHFGGWKQSA-N 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000005094 computer simulation Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 210000001951 dura mater Anatomy 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000005188 flotation Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000003365 glass fiber Substances 0.000 description 2
- 229960002743 glutamine Drugs 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 238000003364 immunohistochemistry Methods 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000002418 meninge Anatomy 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 210000001577 neostriatum Anatomy 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000011148 porous material Substances 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 229960001407 sodium bicarbonate Drugs 0.000 description 2
- 239000012128 staining reagent Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000010408 sweeping Methods 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 229960001814 trypan blue Drugs 0.000 description 2
- 238000011870 unpaired t-test Methods 0.000 description 2
- 238000002689 xenotransplantation Methods 0.000 description 2
- VQJMAIZOEPPELO-KYGIZGOZSA-N (1S,2S,6R,14R,15R,16R)-5-(cyclopropylmethyl)-16-(2-hydroxy-5-methylhexan-2-yl)-15-methoxy-13-oxa-5-azahexacyclo[13.2.2.12,8.01,6.02,14.012,20]icosa-8(20),9,11-trien-11-ol hydrochloride Chemical compound Cl.CO[C@]12CC[C@@]3(C[C@@H]1C(C)(O)CCC(C)C)[C@H]1Cc4ccc(O)c5O[C@@H]2[C@]3(CCN1CC1CC1)c45 VQJMAIZOEPPELO-KYGIZGOZSA-N 0.000 description 1
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 1
- XYGVIBXOJOOCFR-BTJKTKAUSA-N (z)-but-2-enedioic acid;8-chloro-6-(2-fluorophenyl)-1-methyl-4h-imidazo[1,5-a][1,4]benzodiazepine Chemical compound OC(=O)\C=C/C(O)=O.C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F XYGVIBXOJOOCFR-BTJKTKAUSA-N 0.000 description 1
- UGBLISDIHDMHJX-UHFFFAOYSA-N 1-(4-fluorophenyl)-4-[4-(2-methoxyphenyl)piperazin-1-yl]butan-1-one;hydrochloride Chemical compound [Cl-].COC1=CC=CC=C1N1CC[NH+](CCCC(=O)C=2C=CC(F)=CC=2)CC1 UGBLISDIHDMHJX-UHFFFAOYSA-N 0.000 description 1
- JYCQQPHGFMYQCF-UHFFFAOYSA-N 4-tert-Octylphenol monoethoxylate Chemical compound CC(C)(C)CC(C)(C)C1=CC=C(OCCO)C=C1 JYCQQPHGFMYQCF-UHFFFAOYSA-N 0.000 description 1
- 238000000035 BCA protein assay Methods 0.000 description 1
- 101000863717 Bos taurus Deoxyribonuclease-1 Proteins 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 108010041884 CD4 Immunoadhesins Proteins 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 108010057573 Flavoproteins Proteins 0.000 description 1
- 102000003983 Flavoproteins Human genes 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 description 1
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 description 1
- 101000869693 Homo sapiens Protein S100-A9 Proteins 0.000 description 1
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
- 108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102100032420 Protein S100-A9 Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 101000718529 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) Alpha-galactosidase Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 206010054094 Tumour necrosis Diseases 0.000 description 1
- 102000018594 Tumour necrosis factor Human genes 0.000 description 1
- 108050007852 Tumour necrosis factor Proteins 0.000 description 1
- 108010000134 Vascular Cell Adhesion Molecule-1 Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- NNISLDGFPWIBDF-MPRBLYSKSA-N alpha-D-Gal-(1->3)-beta-D-Gal-(1->4)-D-GlcNAc Chemical compound O[C@@H]1[C@@H](NC(=O)C)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@@H](CO)O1 NNISLDGFPWIBDF-MPRBLYSKSA-N 0.000 description 1
- 229940025084 amphetamine Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 239000003855 balanced salt solution Substances 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 238000001218 confocal laser scanning microscopy Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000007822 cytometric assay Methods 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- JVXZRNYCRFIEGV-UHFFFAOYSA-M dilC18(3) dye Chemical compound [O-]Cl(=O)(=O)=O.CC1(C)C2=CC=CC=C2N(CCCCCCCCCCCCCCCCCC)C1=CC=CC1=[N+](CCCCCCCCCCCCCCCCCC)C2=CC=CC=C2C1(C)C JVXZRNYCRFIEGV-UHFFFAOYSA-M 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960004207 fentanyl citrate Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000834 fixative Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- IRYFCWPNDIUQOW-UHFFFAOYSA-N fluanisone Chemical compound COC1=CC=CC=C1N1CCN(CCCC(=O)C=2C=CC(F)=CC=2)CC1 IRYFCWPNDIUQOW-UHFFFAOYSA-N 0.000 description 1
- 229960005220 fluanisone Drugs 0.000 description 1
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- CPBQJMYROZQQJC-UHFFFAOYSA-N helium neon Chemical compound [He].[Ne] CPBQJMYROZQQJC-UHFFFAOYSA-N 0.000 description 1
- -1 hexamycin Chemical compound 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 230000001861 immunosuppressant effect Effects 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 210000005063 microvascular endothelium Anatomy 0.000 description 1
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 description 1
- 229960003793 midazolam Drugs 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000012120 mounting media Substances 0.000 description 1
- MBLBDJOUHNCFQT-UHFFFAOYSA-N n-(3,4,5,6-tetrahydroxy-1-oxohexan-2-yl)acetamide Chemical compound CC(=O)NC(C=O)C(O)C(O)C(O)CO MBLBDJOUHNCFQT-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 238000004091 panning Methods 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 108010091212 pepstatin Proteins 0.000 description 1
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 210000004129 prosencephalon Anatomy 0.000 description 1
- 239000011435 rock Substances 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000717 sertoli cell Anatomy 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Prostheses (AREA)
Description
WO 01/13947 PCT/SE00/01648 1 Reduction of the immunogenicitv of non-human grafts The present invention relates to a transplantation material produced by dissociation of porcine tissue and removal of macrophages and/or microglial cells therefrom. The tissue could be an embryonic or fetal neural tissue and the removal could be effected by exposing the preparation above to antibodies against the Galal-3Galp31-R epitope and a complement reagent. The invention also relates to the use of such a transplantation material for preparing a pharmaceutical preparation useful when transplanting neural tissue. The invention also relates to a kit comprising one or more enzymes for tissue.dissociation, an antibody preparation and a complement reagent.
The invention also relates to a process for removal of macrophages and/or microglial cells from porcine embryonic or fetal neural tissue. Finally, the invention relates to a process for treatment of neurological disorders with such pretreated porcine neural grafts.
Background of the invention Neural transplantation is a potential therapy for Parkinson's and Huntington's diseases (Peschanski et al., 1995; Olanow et al., 1997; Borlongan et al., 1999; Dunnett and Bj6rklund, 1999). Due to the short supply of human donor material (Dunnett and Bjtrklund, 1999), tissue derived from an animal source is considered an appropriate alternative (Isacson and Breakefield, 1997; Edge et al., 1998), and has the advantage of being genetically modifiable (Cozzi and White, 1995; Zawada et al., 1998). When implanted into the striatum of immunosuppressed rats, ventral mesencephalic tissue from pig embryos can grow anatomically correct connections (Isacson et al., 1995) and restore induced behavioural deficits (Huffaker et al., 1989; Galpern et al., 1996). So far, porcine neural tissue has been grafted to 12 Parkinson and 12 Huntington patients in small-scale safety trials (Edge et al., 1998).
Porcine neural grafts are, however, prone to immune-related rejection in the human brain (Deacon et al., 1997). Rejection ofmurine neural grafts can be prevented by WO 01/13947 PCT/SE00/01648 2 treatment of rat hosts with antibodies against T lymphocytes of the immune system (Okura et al., 1997). The human T-cell repertoire includes cells that are activated by porcine major histocompatibility complex (MHC) antigens on porcine cells (direct recognition), and cells that are activated by peptides derived from porcine proteins after processing and presentation by human antigen presenting cells (indirect recognition) (Satake et al., 1994; Dorling et al., 1996). For direct recognition to occur, the porcine donor cells must express class I and/or class II MHC antigens, which are recognised by CD8 and CD4 T lymphocyte cells, respectively. Survival of human neural tissue in mouse brain can be prolonged by depletion of host CD4, but not CD8, T cells (Wood et al., 1996), proving that CD4 T cells are essential for neural xenograft rejection, which is also the case for rejection of non-neural xenografts (Pierson et al., 1989; Kaufian et al., 1995; Korsgren, 1997). In vitro, pig MHC class II antigens elicit a much stronger proliferative response in human T cells than pig MHC class I antigens (Kirk et al., 1993; Kumagai-Braesch et al., 1993; Yamada et al., 1995; Dorling et al., 1996), suggesting that cells which express MHC class II antigens, or have the potential to express these molecules once implanted, contributes heavily to the immunogenicity of the donor tissue. MHC class II antigens have not been reported to occur on neurons (Lampson, 1995).
Cyclosporin, an immunosuppressant that inhibits alloreactivity, is inadequate at protecting porcine xenografts from immune attack in rats (Wennberg et al., 1995).
Continuous cyclosporin treatment of rats hosting porcine neural grafts resulted in some degree of graft survival in 74% of the animals 3-4 months after transplantation (Pakzaban et al., 1995). A Parkinson patient that received porcine neural grafts and continuous cyclosporin treatment had poorly surviving grafts 7.5 months after transplantation, considering that 1.2 x 107 cells were implanted and only 638 dopaminergic cells were present at postmortem histology (Deacon et al., 1997). In the clinical setting, the immunosuppression must, therefore, be more aggressive, which may have serious consequences in terms of side effects (Borlongan et al., 1996), or supplemented by reduction of donor tissue immunogenicity prior to transplantation.
WO 01/13947 PCT/SE00/01648 3 W09637602 Al relates to the use of hepatocytes to treat subjects with disorders characterised by insufficient liver function. Methods are disclosed in order to make these hepatocytes less immunogenic, especially by masking certain antigens, in particular MHC class I antigen. The possibility to remove the Gal(al,3)Gal epitope with a-galactosidase is also discussed, but there is no coupling of an expression of this epitope on macrophages and/or microglial cells and to remove these cells by using the Gal(al,3)Gal epitope. Nothing is mentioned about neural cells.
W09636358 Al relates to reagents and methods in order to inhibit antibody-mediated xenograft rejection by xenogeneic transplant recipients. The object is to block antigen on endothelial cells of the donor organ i e cells being the donor cells at first brought in contact with the blood of the recipient. This document only relates to antibodymediated immunity and the inhibition thereof by using anti-donor antibodies, whereas the present invention relates to the removal of a specific cell population from a neural cell mixture in order to make it less prone to stimulate the T cells of the recipient.
Nothing is mentioned about neural cells and the Gal epitope is only mentioned as a possible antigen to block. Claim I of W09636358 Al is very broad and relates to the inhibition of all possible xenogeneic antigens. The largest difference compared to the process according to the present invention is that the latter relates to depletion of macrophages and/or microglial cells via the Gal epitope and not to blocking thereof.
Koulmanda, M. et al., Xenotransplantation p 295-305 (1995) relates to a method for depletion of immunogenic cells from pancreatic tissue after transplantation.
A
requirement for that is cultivation in 90% 02. The expression of the Gal epitope was studied in this pancreatic tissue as this epitope is important for rejection by being recognized of human antipig antibodies. Nothing is mentioned about neural tissue or expression of the Gal epitope on macrophages and the possibility to use the Gal epitope to deplete this cell population. In this study, anti-CD4 treatment of the recipient has been used to immunosuppress the recipient.
WO 01/13947 PCT/SE00/01648 4 Summary of the invention It has now been shown that when dissociated brain tissue from pig embryos is grown in primary culture, its macrophages and/or microglial cells become autofluorescent, express both classes of MHC antigens and induce proliferation of human T lymphocytes, whereas its astrocytes remain non-autofluorescent, express only MHC class I antigens and generate only a weak proliferative response in human T cells (Brevig et al., 1999). In attempts to remove macrophages and/or microglial cells from porcine brain tissue, a potential target according to the invention is the carbohydrate epitope, Galal-3Galpl3-R (a-galactosyl epitope), which the inventors have now demonstrated on macrophages and/or microglial cells and endothelial cells, but not on neurons and astrocytes, in embryonic pig brain (Sumitran et al., 1999). Human serum contains a high titer of naturally occurring, complement-activating IgG and IgM antibodies against the a-galactosyl epitope (anti-Gal) (Galili, 1993; Rother and Squinto, 1996), but also antibodies against other epitopes expressed in ventral mesencephalon of pig embryos (Sumitran et al., 1999). Purified anti-Gal and complement may, therefore, have the ability to selectively lyse macrophages and/or microglial cells and endothelial cells, and remove these cells from dissociated porcine neural tissue prior to transplantation, for the treatment of neurological disorders.
As described above, neural xenograft survival is compromised by host CD4 T lymphocytes. In order to reduce the immunogenicity of porcine embryonic brain tissue, which is of interest as donor material in therapeutic xenografting for Parkinson's disease, Huntington's disease, multiple sclerosis, epilepsy, stroke, pain, and spinal cord injuries, the possibility of using the a-galactosyl epitope as target for antibody- and complement-mediated removal of macrophages and/or microglial cells has been studied in vitro by the inventors. After exposing brain cells isolated from 27day-old pig embryos to anti-Gal and complement, the remaining cells were (i) analysed by flow cytometry to determine the content of macrophages and/or microglial cells, and (ii) co-cultured with human peripheral blood CD4 T lymphocytes to determine their ability to elicit a proliferative T-cell response, which was assessed by 5 measuring incorporation of tritiated thymidine. Incubation of porcine embryonic brain cells with normal human serum, which contains a high titre of anti-Gal, followed by rabbit complement reduced the number of macrophages and/or microglial cells, both when applied to freshly isolated cells and to cells grown in short-term primary culture.
Cultured porcine embryonic brain cells treated with purified human anti-Gal and rabbit complement contained 0.8% macrophages and/or microglial cells and did not induce proliferation of human CD4 T cells, while brain cells given a control treatment with medium and rabbit complement contained 3.4% macrophages and/or microglial cells and induced a significant proliferative response in human CD4 T lymphocytes.
In the preceding description of the invention, except where the context requires otherwise due to express language or necessary implication, the word "comprise" or variations such as "comprises" or "comprising" is used in an inclusive sense, i.e. to specify the presence of the stated features but not to preclude the presence or addition of further features in various embodiments of the invention.
see* 25 It is to be understood that, if any prior art publication i is referred to herein, such reference does not constitute •eso an admission that the publication forms a part of the common general knowledge in the art, in Australia or any other country.
Detailed description of the invention The invention provides a transplantation material, which has been produced by: 35 dissociation of porcine embryonic or fetal neural tissue, H:\mcamp\keep\retype\44899 Amended Pages 6 Claims AbSorber.doc 14/05/04 6 removal of macrophages and/or microglial cells by exposing the preparation of step to antibodies against the Galal-3Galpl-R epitope and a complement reagent.
Dissociation of a tissue could be either partial or full.
Partial dissociation means dissociation of tissue into a suspension containing cell aggregates. Full dissociation means dissociation of tissue into a single-cell suspension. It is preferred that the partial or full dissociation is effected by the use of one or more enzymes such as proteases and/or deoxyribonucleases. Some examples of such enzymes are given by Barker et al. (1995) such as bovine trypsin from Worthington Biochemical Corporation.
Another suitable enzyme is porcine trypsin, type IX, from Sigma. Some examples of media for washing the dissociated tissue are given by Watts et al. (1998) such as Dulbecco's modified Eagle's medium (DMEM). Phosphate buffered saline (PBS) could also be used. It is also preferred that the complement reagent is rabbit serum or complement purified from rabbit serum.
Examples of antibodies according to the invention are monoclonal or polyclonal antibodies. The antibodies may S: 25 derive from any species, but are preferably human. The i" term monoclonal antibody is art-recognised terminology.
Monoclonal antibodies of the present invention can be prepared according to general methods as described in Kohler et al., 1975. Polyclonal antibodies can, e. be 30 purified from animal or human serum. There is also a possibility to create new molecules that binds to the :00. epitope by means of computer simulation. Methods for computer simulation are known by a person skilled in the art, e. as described in EP 0660 210 A2.
The antibodies according to the invention bind to Galal- 3Galpl-R-terminated epitopes. An example of such an H:\mcamp\keep\retype\P44899 Amended Pages Claims AbSorber.doc 14/05/04 7 epitope is the Galal-3Galpl-4GlcNAc-R epitope. The Galal- 3Gall-R antigen and the isolation thereof is described in Subcellular Biochemistry, Vol. 32: alpha-Gal and Anti-Gal, edited by Galili and Avila. Kluwer Academic/Plenum Publishers, New York, 1999; Liu et al. (1997); and Hallberg et al. (1998).
The invention further provides the use of the abovementioned transplantation material for preparing a pharmaceutical preparation which is useful when transplanting neural tissue.
The present invention also provides a kit, for use in treating a porcine tissue in order to reduce its immunogenicity, comprising one or more enzymes for tissue dissociation, a preparation of an antibody against the Galal-3Galpl-R epitope, and a complement reagent.
It is preferred that the antibody is a polyclonal antibody. It is especially preferred that the antibody is of human origin. It is also preferred that the antibody binds to macrophages and/or microglial cells. Examples of enzymes and complement reagents are given above.
25 The invention also provides a process for removal of macrophages and/or microglial cells from porcine embryonic *o or fetal neural tissue, wherein the neural tissue is dissociated and treated with an antibody against the Galal-3-Galpl-R epitope 30 the macrophages and/or microglial cells are depleted from the preparation of step by exposing the g o. preparation in step to the antibody coupled to a carrier or by flow sorting, or the macrophages and/or microglial cells are depleted 35 from the preparation of step by treating the preparation of step with a complement reagent.
H:\mcamp\keep\retype\P44899 Amended Pages Claims AbSorber.doc 14/05/04 7a It is preferred that the porcine embryonic or fetal neural tissue is dissociated by the use of one or more enzymes such as proteases and/or deoxyribonucleases. It is also preferred that the antibody is a polyclonal antibody such as an antibody of human origin. It is also preferred that the complement is rabbit serum or complement purified from rabbit serum. Examples of suitable carriers are paramagnetic beads or a plastic surface.
It is preferred to dissociate the donor material and use antibody- and complement- mediated lysis, because even macrophages and/or microglial cells within small cell clusters can be removed by this mechanism.
It is also possible to convert the donor material into a single-cell suspension and physically remove macrophages and/or microglial cells e. g. by panning, paramagnetic beads or flow sorting although this may lower the amount of usable nerve cells. See Current Protocols in Immunology, edited by Coligan, J. E. et al. 1993, vol. 1- 3, John Wiley Sons, Inc.
invention also provides a process for treatment of 25 neurological disorders, comprising the steps porcine embryonic or fetal neural tissue is dissociated, *o* oe *o* *oo *o~ eeo *•o *oo o H:\mcamp\keep\retype\P44899 Amended Pages Claims AbSorber.doc 14/05/04 WO 01/13947 PCT/SE00/01648 8 the dissociated tissue is treated with antibodies against the Galal-3Gal 31-R epitope and a complement reagent in order to remove macrophages and/or microglial cells, the dissociated and antibody- and complement-treated tissue is transplanted into the human body.
Preferably, the disorders are selected from the group consisting of Parkinson's disease, Huntington's disease, multiple sclerosis, epilepsy, stroke, pain, and spinal cord injunes.
Instead of transplanting whole suspensions prepared from porcine brain tissue, the inventors propose that the dissociated tissue should be pretreated with anti-Gal and complement, the effect of which is shown in Figure 12. If the pretreatment with anti- Gal and complement can enhance survival of porcine neural grafts in humans, it may serve as a simple and inexpensive way of reducing donor tissue immunogenicity prior to clinical neural xenotransplantation.
After neural xenotransplantation, both direct and indirect recognition of the graft may occur, but the relative strength of these two mechanisms is not known in the pig-toman xenograft situation (Gill and Wolf, 1995; Auchincloss and Sachs, 1998). The inventors have focused on direct recognition, but the pretreatment with anti-Gal and complement may also reduce indirect recognition (Brevig et al., in press). The effect of indirect recognition may be explained by the removal of cells and thus proteins carrying the a-galactosyl epitope, which can be opsonized by host anti-Gal for endocytosis, processing and presentation by host antigen-presenting cells. Because neurons may be recognized by T cells via the indirect pathway, porcine neural xenografts cannot be made completely non-immunogenic.
WO 01/13947 PCT/SE00/01648 9 Short description of the figures Figure 1. Flow cytometric analysis of unstained brain cells from 28-day-old pig embryos.
Figure 2. Expression of CD18, CD56, CD44, CD4, and GFAP by cells isolated from 28-day-old embryonic pig brains and grown for 14 days in primary culture.
Figure 3. Phagocytosis of Escherichia coli by cultured cells from 28-day-old embryonic pig brains.
Figure 4. Flow sorted astrocyte and macrophage microglial populations, separated on the basis of CD56 expression.
Figure 5. Expression of a-galactosyl epitopes on suspended ventral mesencephalic cells and microvascular endothelial cells isolated from porcine liver.
Figure 6. Western blot analysis of BS-IB4 reactive, solubilized glycoprotein isolated from cell membranes.
Figure 7. Saggital section of the ventral mesencephalon of a 27-day-old pig embryo stained immunohistochemically for tyrosine hydroxylase.
Figure 8. Expression of the a-galactosyl epitope on cultured porcine embryonic brain cells.
Figure 9. Effect of human serum and rabbit complement on cultured and freshly isolated porcine embryonic brain cells.
Figure 10. Reactivity towards the a-galactosyl epitope of the antibodies purified from normal human serum using porcine thyroglobulin.
WO 01/13947 PCT/SE00/01648 Figure 11. Proliferative response of CD4 T lymphocytes from two human individuals when co-cultured with pretreated porcine embryonic brain cells.
Figure 12. Summary of the effect of anti-Gal and complement on dissociated porcine brain tissue in the clinical situation and in an in-vitro model.
Figure 13. Effect of the pretreatment on porcine neural graft function in a rat model of Parkinson's disease.
Figure 14. Histology of a graft derived from porcine embryonic VM tissue pretreated with anti-Gal and complement.
The invention will now be described by reference to some non-limiting examples As used herein, the following terms have the following meanings: a-galactosyl epitope means Galal-3Gall1-R (where R is the rest of the molecule), anti-Gal means antibodies against Galal-3Galpl -R (where R is the rest of the molecule), BSA means bovine serum albumin, DMEM means Dulbecco's modified Eagle's medium, EDTA means ethylenediaminetetraacetic acid, FCS means fetal calf serum, FITC means fluorescein isothiocyanate, FBS means fetal bovine serum, Gal means D-galactose, GlcNAc means D-N-acetylglucosamine, Ig means immunoglobulin, mAb means monoclonal antibody, PBS means phosphate buffered saline, WO 01/13947 PCT/SE00/01648 11 PMSF means phenylmethane sulfonyl fluoride, PLMEC means porcine liver microvascular endothelial cell, RPE means R-phycoerythrin, TBS means Tris-buffered saline, TH means tyrosine hydroxylase, TNF means tumour necrosis factor, VCAM means vascular cell adhesion molecule, and VM means ventral mesencephalon.
All technical and scientific terms used herein are, unless otherwise defined, intended to have the same meaning as commonly understood by one of ordinary skill in the art. By the expression "comprising", we understand including but not limited to. Techniques employed herein are those that are known to one of ordinary skill in the art unless stated otherwise. Publications mentioned herein are incorporated by reference.
Examples Materials and methods For Example 1 and 2 (See also for Example 4-7) Porcine fetal brain cells. Brain cells were isolated from whole brain or ventral mesencephalon of 28, 35, 42, and 56 days old pig fetuses (Table Brains isolated from each of the 12 litters of 6-15 fetuses were pooled in Gey's Balanced Salt Solution (Life Technologies, Scotland) and meninges were carefully removed. The brains were cut into small pieces, transferred to brain-cell medium (Eagle's Minimum Essential Medium with Earle's Salts supplemented with L-glutamine, amino acids, vitamins (all Life Technologies), penicillin, hexamycin, and sodium bicarbonate) with 20% heatinactivated (56 0 C, 30 min) horse serum (Life Technologies), triturated with a flamepolished pipette, and finally filtered through a Nitex filter with 80-pm pores. The WO 01/13947 PCT/SE00/01648 12 filtrates were diluted in brain-cell medium with 20% horse serum to give total volumes of 10, 20, 30, or 50 ml per 28, 35, 42, or 56 days old brain, respectively.
The brain cells were analysed directly after isolation or after 12-14 days in primary culture. Cultures were prepared by adding 5.0 ml cell suspension, prepared as described above, to poly-D-lysine (Sigma, USA) coated culture flasks (50-ml flasks; Nunc, Denmark), followed by incubation at 370C in a humidified atmosphere of
CO
2 in air. After 2 days, when the cells had attached, the medium was changed to brain-cell medium with 20% horse serum, and subsequently twice a week to brain-cell medium with 10% horse serum.
The cultured brain cells were detached by gently sweeping the bottoms of the culture flasks with a plastic pipette (culture flasks were checked by microscopy to ensure that all cells had detached), transferred to V-bottomed tubes (content of one flask to one tube) and centrifuged (100 g, 10 min). The supernatants were discarded, each tube was given either 500 l1 or 500 p~ lymphocyte medium and the cells were resuspended using a syringe with a needle of 0.5 mm internal diameter. The tubes were left for min at room temperature to sediment cell clusters, and the supernatants with single cells in suspension were harvested and used for subsequent analyses.
Staining reagents. For immunofluorescence staining of the brain cells, the following primary antibodies and antibody-fluorochrome conjugates were used: mouse anti- MHC I IgG2 (immunogen: pig thymus; 1:10; clone PT85A; Veterinary Medical Research and Development (VMRD), USA), mouse anti-MHC II IgG 2 a (immunogen: thymus from pig and other species; 1:10; clone TH16B; VMRD), mouse anti-pig CD4 IgG 2 a clone PT90A; VMRD), mouse anti-pig CD44 IgG2a clone PORC24A; VMRD), mouse anti-human CD18 IgGi FITC clone MHM23; DAKO, Denmark), mouse anti-human CD56 IgG, RPE clone MY31; BD), or polyclonal rabbit anti-cow GFAP (1:10; DAKO). Goat anti-mouse immunoglobulins F(ab') 2
RPE
(1:10; DAKO) was used as secondary reagent for the MHC antibodies and the antibodies against CD4 and CD44. Swine anti-rabbit immunoglobulins FITC (1:10; WO 01/13947 PCT/SE00/01648 13 DAKO) was used as secondary antibody for the GFAP antibody. Samples exposed to species- and isotype-matched irrelevant antibody (mouse IgG 2 a negative control (1:1; DAKO) or mouse IgG, negative control FITC/RPE/Cy5 DAKO)) or secondary antibody only were used as negative controls. According to the manufacturers, primary antibodies against antigens from other species than pig cross-reacted strongly with the corresponding pig antigens. Higher concentrations of antibodies than indicated did not give stronger staining. Staining reagents for demonstration of phagocytosis are given below.
Staining procedures. Brain cells from cultures derived from the same brains were pooled prior to staining to eliminate possible variability between cultures. Volumes of 100 gl cell suspension containing 1.0x 106 freshly isolated or cultured brain cells were transferred to Falcon tubes (BD) and given 10 tl antibody. After 30 min in the dark at room temperature, the cells were washed twice in PBS (250 g, 5 min) and resuspended in 100 pl PBS for indirect immunostaining or 500 1l PBS for direct immunostaining.
Samples for indirect immunostaining were given 10 0l secondary antibody, incubated and washed as described above, and resuspended in 500 pl PBS. Prior to staining for GFAP, the cells were fixed and permeabilized in the Falcon tubes by incubating them for 10 min in 2.0 ml FACS Lysing Solution and subsequently for 10 min in ml FACS Permeabilizing Solution (BD).
For demonstration ofphagocytosis, 0.5 mg fluorescein-labelled Eschericia coli BioParticles (Molecular Probes, USA) was added to the medium of brain-cell cultures.
After 30 min of incubation at 37 0 C, the cells were washed twice in PBS, detached, dissociated and analysed by flow cytometry, fluorescence microscopy or confocal laser microscopy. Prior to receiving the E. coli BioParticles, cultures to be analysed by confocal laser microscopy were given 20 uil 1,1 '-dioctadecyl-3,3,3',3'tetramethylindocarbocyanine perchlorate (Dil; Molecular Probes) stock solution mg Dil per ml 99% ethanol), incubated for 2 h at 37 0 C and washed twice in brain-cell medium with 10% horse serum.
WO 01/13947 PCT/SE00/01648 14 Flow cytometry. Brain cells were stained as described above, and 1.0x 0 4 ungated events were acquired from each sample on a FACScan flow cytometer
A
forward-scatter threshold was set to exclude subcellular debris. The instrument settings were identical for all acquisitions, except for the fixed cells, where the forward-scatter threshold was reduced.
Confocal laser scanning microscopy. Drops of suspended brain cells were placed on microscopy slides and covered by coverslips for ordinary fluorescence microscopy.
Suitable parts of the samples were then scanned by a Leica TCS 4D DM R confocal laser scanning microscope (Leica, Germany) in dual-channel mode using excitation wavelengths of 488 and 568 nm, detectors with fluorescein and rhodamine optical filter sets, and linear AD converting.
Flow sorting. In order to separate astrocytes and macrophages/microglial cells, singlecell suspensions of cultured brain cells, prepared as described above, were sorted at a rate of 2-3x 103 cells/s on a FACSVantage cell sorter (BD) equipped with a Helium- Neon laser (488 nm), an FL1/FL2 beam splitter (560 nm), and FL1 (530 15 nm) and FL2 (575 13 nm) filters. Six times 107 brain cells, in 5.0 ml PBS with 2% FCS, were given 200 pl mouse anti-CD56 IgG, RPE, incubated for 30 min at 4 0 C, washed twice in CellWash with 2% FCS (250 g, 5 min) and sorted by setting rectangular gates in a green-fluorescence/orange-fluorescence plot to sort CD56-positive cells (astrocytes) into one tube, and autofluorescent, CD56-negative cells (macrophages/microglial cells) into another. The sample fluid was PBS with 2% FCS. FACSFlow (BD) was used as sheat fluid. A forward-scatter threshold was set to exclude subcellular debris.
The purity of the cell sorted populations was determined by flow cytometry without further staining of the cells. The viability of the macrophages/microglial cells was determined by flow cytometry after staining with propidium iodide. The viability of the astrocytes was determined by counting the blue cells and the total number of cells, 10 min after mixing aliquots of 0.4% trypan blue solution (Sigma) and cell suspension.
WO 01/13947 PCT/SE00/01648 Mixed lymphocyte-brain cell culture. Mononuclear blood cells (lymphocytes and monocytes) from 3 healthy blood donors (H-3970, H-3977, and H-8053) were isolated from buffy coats by flotation and cryopreserved as earlier described (Brevig et al., 1997). Prior to use, the cells were thawed in a water bath (37 0 washed (500 g, min) 3 times in RPMI (Life Technologies), and left for 24 h in lymphocyte medium RPMI 1640 with HEPES, 10% heat-inactivated FCS, 100 IU/ml penicillin, 100 tg/ml streptomycin, and 2.0 mM L-glutamine; all Life Technologies) at 37 0 C in a humidified atmosphere of 5% CO 2 in air. Volumes of 100 l lymphocyte medium containing 2.0x 105 human mononuclear blood cells (responders) were dispensed in wells of U-bottomed microtiter plates (Nunc). Unseparated brain cells, sorted brain cells, and allogeneic mononuclear blood cells (stimulators) were y-irradiated (50 Gy), and 2.0x104 cells in 100 gil lymphocyte medium were added to wells with responders (3 or 5 wells per combination). Wells receiving responders and lymphocyte medium but no stimulators were used as negative controls (5 or 12 wells per combination).
Each well was given 1.0 tCi 3 H-thymidine (Amersham, UK) 24 h prior to cell harvest. After 4 days of incubation at 37 0 C in a humidified atmosphere of 5% CO 2 in air, cells were harvested with a cell collection system (Skatron, Norway) and counted in a P-counter (2000CA Tri-Carb; Packard, USA).
Statistical analysis. The proliferation data were analysed by one-way analyses of variance (ANOVAs) and one-sided, unpaired t tests.
For Example 3 (See also for Example 4-7) Cell culture. The immortalised human umbilical vein endothelial cell line, ECV304 (ATCC; CRL-1998), was cultured in DMEM/FBS. Porcine liver microvascular endothelial cells (PLMECs) were isolated from fresh pig livers obtained from the local slaughter house. The specimens were chopped into pieces in medium containing 0.05% collagenase (cat. no. 1 088 793; Boehringer Mannheim, Germany) and 0.002% DNase I type II from bovine pancreas (cat. no. D-4527; Sigma, USA), WO 01/13947 PCT/SE00/01648 16 followed by digestion at 37°C for 30-45 min. The cell suspension was filtered to remove undissociated tissue, washed three times with PBS, and cultured for 1 week in 0.2% gelatin-coated 25 cm 2 flasks (Falcon, USA) using the medium indicated below.
Expanded cells were activated for 18 h with 100 U/ml human recombinant TNFca (Genzyme, USA), incubated on a rock n' roller for 1 h at room temperature with 4g (1 mg/ml) of anti-pig VCAM antibodies (clone 5D11; Alexion Pharmaceuticals, USA), washed once with PBS, and incubated with 100 gl of paramagnetic goat antimouse dynabeads (Dynal, Norway) at 4 °C for 45 min followed by immunomagnetic selection on a magnet. Positively selected cells were washed three times with PBS and cultured in gelatin-coated, six-well tissue culture plates (Falcon) in DMEM containing FBS (Gibco, USA), penicillin (100 IU/ml; Sigma) and streptomycin (100 ag/ml; Sigma), and 1 ml/100 ml medium of endothelial cell growth factor (cat. no. E-9640; Sigma). On the second day of culturing, the beads were washed away using PBS. The cells were allowed to grow to confluence before subculturing. Endothelial cells were characterised by morphology, and by flow cytometric phenotyping using anti-Eselectin (clone BBIG-E4; cat. no. BBA 16; R&D systems, and anti-pig VCAM antibodies. More than 95 of the cells were endothelia cells.
Isolation ofpig embryonic ventral mesencephalic cells. Ventral mesencephalic (VM) regions were obtained from E26-27 pig embryos of the Pigham strain (derived from a cross between Swedish Landrace x Yorkshire sows and Hampshire boars; Nyholms Breeding Farm, Sweden). Pigs were bred and euthanized according to local and national animal ethics regulations. The VM cells contained approximately 10-15% dopaminergic cells, the rest being other neurons, glia, and endothelial cells. The tissue was dissected in Hank's balanced salt solution with 0.3 pM lazaroid U-83836E (Upjohn Inc., USA) (Nakao et al., 1994). A VM tissue specimen, about 2 x 2 x 1 mm was cut into 4-6 smaller pieces, and these were transferred to cold storage medium (Grasbon-Frodl et al., 1996) and shipped to Huddinge Hospital for analysis the same or the following day. The tissue was then triturated into a cell suspension by several passages through a pipette. Prior to shipping and in vitro analysis, the viability was checked using ethidium bromide.
WO 01/13947 PCT/SE00/01648 17 Flow cytometric assays. Five times 105 VM cells in 50 pl PBS were incubated with pl human AB serum, anti-Gal antibody-depleted AB serum or RPMI 1640 medium for 1 h at 22 The cells were washed three times with PBS containing 0.1% sodium azide. Ten tl of 1:4 diluted FITC-conjugated F(ab)' 2 fragments of goat anti-human IgG or IgM antibodies (109-096-098 and 109-096-129, respectively; Jackson ImmunoResearch Labs, USA) were added, and the samples were incubated on ice in the dark for 25 min. The cells were washed and then analysed by flow cytometry. agalactosyl epitope expression was estimated by incubating VM cells or PLMECs with biotinylated Bandereia Simplicifolia isolectin B4 (4 p.g/ml; cat.no. L-2140; Sigma) followed by detection with FITC-conjugated avidin (cat.no. 55880; Organon Teknika, USA) diluted 1:2000 in I BSA/PBS. Alternatively, 200 J1 of rabbit serum (cat. no.
439665, Biotest AG, Germany) was added to tubes containing 5 x 105 VM cells in pl PBS and 50 pl human AB serum, anti-Gal antibody-depleted AB serum or RPMI 1640 medium and incubated again, now for 1 h. Dead cells were detected by adding il propidium iodide (PI; 3.2 mM in PBS) immediately prior to analysing the samples on the flow cytometer (FACScan; Becton Dickinson, USA) equipped with an argon laser exciting at 488 nm (Jacobs et al., 1983). Data was collected with logarithmic amplification and fluorescence intensity was displayed as arbitrary linear units.
Fluorescence signals from 10,000 cells were acquired.
Staining ofporcine embryonic VM tissue with anti-tyrosine hydroxylase, antimonocyte/macrophage antibodies or the isolectin Bandereia Simplicifolia IB4. Whole heads from E26/E27 embryos were cut, immersion fixed in cold 0.1 M phosphate buffered 4% paraformaldehyde (pH 7.4) over night, followed by an incubation in a sucrose-PBS solution for at least 24 h. The specimens were frozen, and four series of 40-gm-thick coronal sections were cut on a sliding microtome. Free-floating sections were stained.
For tyrosine hydroxylase and microglial-cell immunostaining, standard immunohistochemical methods were used (Duan et al., 1995). Endogenous peroxidase WO 01/13947 PCT/SE00/01648 18 activity was removed with a 3% H202/10% methanol solution, followed by a 1-h incubation in 5% swine serum. Sections were incubated over night in rabbit anti-TH (1:500; Pel-Freez, USA) or in mouse anti-human monocyte/macrophage (1:500; clone MAC387; IgGI; Serotec, UK) mAbs diluted in PBS (pH=7.2-7.4) with 0.3% Triton X- 100 (PBS-X) at room temperature. The latter antibody binds microglial cells and crossreacts with the porcine antigen (Serotec). The following day, sections were rinsed three times in PBS-X and incubated for 1 h with biotinylated swine anti-rabbit antibody (1:200; DAKO, Denmark) or with a polyclonal biotinylated horse anti-mouse IgG antibody (1:200; clone BA-2001; Vector Labs, USA), respectively. After rinsing in PBS-X, the VectastainTM standard peroxidase ABC kit was used (Vector Labs).
After 1 h, the sections were washed three times in PBS-X and visualised using a DAB (3.3'-diaminobenzidine) kit, (Vector Labs). Sections were mounted on gelatin slides, dehydrated using standard alcohol/xylene reagents, and cover-slipped with DePeX (BDH Labs, UK).
For staining with isolectin Bandereia Simplicifolia IB4 (BS-IB4), sections were treated with a 3% H202/10% methanol solution to block endogenous peroxide activity, followed by a 1 h incubation in 1% BSA blocking solution. Sections were incubated over night in a 4 ig/ml solution of biotinylated BS-IB4 (L-2140; Sigma) diluted in PBS (pH=6.8) containing 0.2 mM CaCI2 (PBS-Ca). On the following day, sections were washed in PBS-Ca three times and then incubated at room temperature with the AB solution contained in the VectastainTM standard peroxidase ABC kit (Vector Labs).
After rinsing in PBS-Ca, the sections were reacted with a DAB solution prepared using the Vector
T
M Dab kit (Vector Labs). Sections were mounted on gelatin slides, dehydrated using standard alcohol/xylene reagents, and cover-slipped with DePeX (BDH Labs).
Isolation of endothelial and VM cell membranes. Cells were washed once with PBS containing 1 mM PMSF and kept frozen at -70 °C until use. Following six cycles of freeze-thawing, cells were homogenised on ice in PBS/I mM PMSF using a Dounce homogeniser (approximately ten strokes). Nuclei were pelleted by centrifugation for WO 01/13947 PCT/SE00/01648 19 minutes at 3,000 g, the supernatant was collected, and the pellet was resuspended in the same buffer and centrifuged again. This was repeated, and the pooled supematants were ultracentrifuged at 100,000 g for 1 hour and 100 min in a Ti 75 rotor, the pellet resuspended in PBS/I mM PMSF and overlayed on top of an equal volume of a 35 sucrose in PBS solution. Following centrifugation at 100,000 g for 1 hour without brake in a SW 40 rotor, the membranes were collected as a cloudy interphase, and again pelleted by centrifugation at 40,000 g for 1 h. VM and endothelial cell membrane proteins were solubilized in 10 mM Tris-HCI (pH=7.5) with 100 mM NaCI, mM EDTA, and 1 Igepal CA-630 (1-3021; Sigma) containing 1 mM PMSF (P- 7626; Sigma), 1 ig/ml pepstatin A (P-4265; Sigma) and 1 tg/ml leupeptin (L-2023; Sigma). An equal volume of solubilized cell membrane proteins and 2 x reducing sample buffer were mixed and applied onto the gel.
SDS-PAGE and Western blotting. SDS-PAGE was run by the method of Laemmli (Laemmli et al., 1970) with 5 stacking gels and 8 resolving gels using a vertical Mini-PROTEAN II electrophoresis system (Bio-Rad, USA). Separated proteins were electrophoretically blotted onto HybondT-C extra membranes (Amersham, UK) using a Mini Trans-Blot electrophoretic transfer cell (Bio-Rad). Protein gels were stained using a silver staining kit according to the instructions of the manufacturer (Bio-Rad).
Following blocking for at least 2 h in 3 BSA in PBS, the membranes were probed for 2 h at room temperature with peroxidase-conjugated Bandereia Simplicifolia isolectin B4 (L-5391, Sigma) diluted to 1 gg/ml in PBS (pH=6.8) containing 0.2 mM CaCI 2 The membranes were washed five times with PBS and bound isolectin was visualised by chemiluminescence using the ECL T M kit (Amersham).
When membranes were probed with human serum, they were blocked over night with 3 BSA in Tris-buffered saline with 0.05% Tween 20 (TTBS), incubated for 1 h at room temperature with non-diluted AB serum or anti-Gal antibody-depleted AB serum, washed five times with TTBS, and incubated for 1 h at room temperature with peroxidase-conjugated, F(ab)' 2 fragments of goat anti-human IgG or IgM antibodies (cat. nos. 109-036-098 and 109-036-129, respectively; Jackson ImmunoResearch WO 01/13947 PCT/SEO0/01648 Labs.). Following washing in TTBS, antibody-binding components were detected using the ECL T M kit (Amersham).
For Example 4-7. Also for Example 1-3 unless specified otherwise.
Isolation and primary culture ofporcine embryonic brain cells. Brains were dissected from 27-day-old pig embryos of the Pigham strain in Hank's balanced salt solution with 0.3 gM lazaroid U-83836E (Upjohn Inc., USA). Brain cells were isolated and grown in primary culture as described elsewhere (Brevig et al., 1997). Briefly, the meninges were removed, and the brains from each litter were pooled and cut into small pieces, which were transferred to brain-cell medium (Eagle's minimum essential medium with Earle's salts supplemented with heat-inactivated (56°C, 30 min) fetal calf serum (FCS), L-glutamine, amino acids, vitamins, penicillin, streptomycin, and sodium bicarbonate (all Life Technologies Inc., USA)). The tissue pieces were triturated with a flame-polished pipette, and the resulting cell suspension was filtered through an 80-pm-pore nylon mesh (Streno, Denmark) before diluting in brain-cell medium with 20% FCS (10 ml per brain). Aliquots of 5.0 ml cell suspension were added to poly-D-lysine (Sigma, USA) coated 50-mi culture flasks (Nunc, Denmark), and incubated at 37 0 C in a humidified atmosphere of 5% CO 2 in air. The medium was changed after 3 days, and again on day 6 and 9, now to brain-cell medium with FCS. After 10-12 days, cultured brain cells were detached by gently sweeping across the bottoms of the culture flasks with a plastic pipette, transferred to 10-ml tubes (content of one flask to one tube), and centrifuged (100 g, 10 min). Supernatants were discarded, and the cells in the pellet were resuspended in 500 gl PBS with 2% FCS using a syringe with a needle of 0.5 mm internal diameter. The tubes were left for min at room temperature to sediment cell clusters, and the supernatants with single cells in suspension were pooled and used for subsequent analyses.
Bandereia Simplicifolia isolectin staining ofporcine embryonic brain cells. Suspended and adherent, cultured porcine embryonic brain cells were stained with Bandereia Simplicifolia isolectin B4 (BS-IB4) in order to determine the expression of the a- WO 01/13947 PCT/SE00/01648 21 galactosyl epitope by flow cytometry and light microscopy, respectively. Suspensions of 5.0x105 brain cells in 100 l PBS were incubated with or without 3.0 .g FITCconjugated BS-IB4 (Sigma) at 4 0 C for 30 mm, washed twice in PBS (250 g, 5 min), and analysed by flow cytometry as described below. Brain cells adherent to a culture dish were fixed in 4% paraformaldehyde in PBS for 30 min, permeabilized by 1% Triton X-100 (Sigma) in Tris-buffered saline (TBS) for 15 min, and stained by incubation with biotinylated BS-IB4 (100 .g/ml TBS; Sigma) for 60 min, peroxidaseconjugated streptavidin (1:200 in TBS; DAKO, Denmark) for 60 min, and finally 0.05% 3,3'-diaminobenzidine (DAB; Sigma) in TBS for 15 min. Between the incubations, which were all at 20 0 C, the cells were thoroughly rinsed with TBS. After incubation with DAB, the cells were rinsed with TBS and distilled water, covered with Aquamount (BDH Laboratory Supplies, UK), and examined in an inverted light microscope.
Treatment ofporcine embryonic brain cells with human serum and rabbit complement.
Freshly isolated porcine embryonic brain cells were split into three aliquot suspensions (3.0x10" cells in 2.0 ml PBS), of which one received a treatment with human serum and rabbit complement: the cells were given 8.0 ml heat-inactivated human serum (pooled from blood type AB donors), incubated for 60 min at 4 0 C, washed in cold PBS (400 g, 5 min), resuspended in 5.0 ml Low-Tox-M rabbit complement (lyophilised content of one vial was reconstituted to 10 ml with PBS; Cedarlane Laboratories Ltd., Canada), incubated for 60 min at 37 0 C, and finally washed in PBS (400 g, 5 min). The three cell suspensions were cultured for 10 days in separate culture flasks as described above, and cells from one culture flask, not treated prior to culture, then received an identical treatment with human serum and rabbit complement. Cells from all three cultures were analysed by flow cytometry without prior staining, to determine the content of autofluorescent macrophages/microglial cells.
Isolation of human CD4 T lymphocytes. Mononuclear cells (lymphocytes and monocytes) from two healthy blood donors were isolated from buffy coats by flotation as earlier described (Brevig et al., 1997), cooled on ice for a few minutes, and mixed WO 01/13947 PCT/SE00/01648 22 with washed, paramagnetic Dynabeads M-450 CD4 (Dynal, Norway) to a bead-to-cell ratio of 0.6. The tubes were incubated head-over-tail at 4 0 C for 40 min and left in a magnetic particle concentrator (MPC; Dynal) for 3 min. The supematants were discarded, and the positively isolated cells on the beads were washed five times in PBS with 2% FCS and resuspended in Detachabead CD4/CD8 reagent (1.0 pl per 2.8x beads; Dynal). After incubation head-over-tail at 20 0 C for 50 min, the tubes were given 5 ml PBS with 2% FCS and left for 3 min in the MPC. The positively isolated cells in the supernatants were transferred to new tubes and washed, in PBS with 2% FCS, once with the MPC and once by centrifugation (500 g, 10 min).
The purity of the isolated CD4 T lymphocytes was analysed by flow cytometry after incubating 5.0x 105 cells in 100 gl PBS with 10 pl mouse anti-human CD3/4 FITC/RPE (Becton Dickinson, USA) at 4 0 C for 30 min and washing twice in PBS (250 g, 5 min). Isolated cells from individual A and B contained 99.1% and 99.7% double-positive cells, respectively.
Mixed lymphocyte-brain cell culture. A suspension of porcine embryonic brain cells, prepared as described above, were split into aliquots containing 3.0x 10 6 cells in 190 pl PBS with 2% FCS, and each aliquot was given 1.0 ml of one of the following reagents: human IgG (10 mg/ml), human IgM (2.0 mg/ml), human anti-Gal (100 heatinactivated human serum (pooled from blood type AB donors), or lymphocyte medium RPMI 1640 with HEPES, 10% heat-inactivated FCS, 100 IU/ml penicillin, 100 gg/ml streptomycin, and 2.0 mM L-glutamine; all Life Technologies). Human IgG, IgM, and anti-Gal were diluted in lymphocyte medium just prior to use. After 60 min at 4°C, the cells were washed in cold lymphocyte medium (400 g, 5 min) and resuspended in 1.0 ml Low-Tox-M rabbit complement (lyophilised content of one vial was reconstituted to 10 ml with lymphocyte medium). After 60 min at 37 0 C, the cells were washed (400 g, 5 min), resuspended in lymphocyte medium, and counted. About of the brain cells were lost in the incubation and centrifugation steps. The cells were y-irradiated (40 Gy), and 2.0x 10' brain cells in 100 p.l lymphocyte medium were WO 01/13947 PCT/SE00/01648 23 dispensed in wells of round-bottomed, 96-well plates (Nunc). Volumes of 100 p1 lymphocyte medium containing 2.0x 10 5 human CD4 T lymphocytes were added in triplicate to wells with brain cells. Wells receiving CD4 T cells and lymphocyte medium but not brain cells were used to determine the background proliferative activity of the CD4 T cells. Each well was given 1.0 tCi 3 H]thymidine (Amersham, UK) 24 h prior to cell harvest. After 3-7 days of incubation at 37CC in a humidified atmosphere of 5% CO 2 in air, cells were harvested onto glass fibre filters and counted for 15 min in a 1450 MicroBeta Trilux P-counter (Wallac, Finland).
The brain-cell suspensions were analysed by flow cytometry without prior staining and after staining with propidium iodide (1.0 gg/ml PBS; Sigma) to determine the relative number of macrophages/microglial cells and viable cells, respectively. Samples given propidium iodide were analysed after 10 min in the dark at room temperature.
Flow cytometry. From each sample, 1.Ox 104 ungated events were acquired on a FACSort flow cytometer (Becton Dickinson). A forward-scatter threshold was set to exclude subcellular debris.
For Example 8 (See also for Example 4-7 and Example 4 itself) Isolation and primary culture ofporcine embryonic brain cells. Whole forebrains were dissected from 27-day-old pig embryos, dissociated, and grown in Eagle's minimum essential medium with Earle's salts supplemented with heat-inactivated (56 0 C, 30 min) fetal calf serum (FCS), L-glutamine, amino acids, vitamins, penicillin, streptomycin, and sodium bicarbonate (all from Life Technologies, USA) in poly-D-lysine (Sigma Chemical Co., USA)-coated culture flasks, as described in detail elsewhere (Brevig et al., 1999). After 10 or 12 days in culture (change of medium every third day), brain cells were detached and dissociated, washed (100 g, 10 min), and resuspended in phosphate-buffered saline (PBS, pH 7.4) with 2% FCS.
WO 01/13947 PCT/SE00/01648 24 Purification ofanti-Gal from human serum. As in Example 4 but only purification of human anti-Gal from serum pooled from more than 20 healthy, blood type AB donors using beaded agarose with porcine thyroglobulin (Sigma).
Isolation ofhuman CD4 T lymphocytes. Human CD4 T lymphocytes were isolated from buffy coats of two healthy blood donors using Dynabeads M-450 CD4 (Dynal, Norway) and the corresponding Detachabead reagent (Dynal), as described (Brevig et al., 1997). The purity was analysed by flow cytometry after staining with mouse antihuman CD3/4 FITC/RPE (Becton Dickinson). Cells isolated from individual A and B contained 99.1% and 99.7% double-positive cells, respectively. Volumes of 100 Pl medium containing 2.0 x 105 human CD4 T cells were added in triplicate to wells with brain cells or medium only. Each well was given 1.0 ICi 3 H]thymidine (Amersham, UK) 24 h prior to cell harvest. After 3-7 days of incubation at 37 0 C in a humidified atmosphere of 5% CO 2 in air, cells were harvested onto glass fibre filters and counted for 15 min in a 1450 MicroBeta Trilux p-counter (Wallac, Finland).
Donor tissue isolation andpretreatment. Ventral mesencephalon (VM) was dissected from 27-day-old pig embryos of crown-rump length 19-21 mm. Tissue pieces from 16 embryos were pooled in 5.0 ml Dulbecco's modified Eagle medium (DMEM, cat. no.
41966-011; Life Technologies, Scotland) containing 0.1% porcine trypsin, type IX (cat. no. T-0134; Sigma) and 0.05% bovine deoxyribonuclease I, type IV (cat. no. D- 5025; Sigma), incubated at 37 0 C for 20 min, washed five times in DMEM, and triturated in 1.0 ml DMEM containing 0.05% deoxyribonuclease using flame-polished glass pipettes of progressively smaller apertures. The resulting cell suspension was split into two aliquots, which were given 300 gg human anti-Gal in 600 pl DMEM (500 ig/ml) or 600 tl DMEM only (control). After 60 min at 4°C, the cell suspensions were washed in DMEM (200 g, 5 min), resuspended in 5.0 ml DMEM containing Low-Tox-M rabbit complement (lyophilized content of one vial was reconstituted to ml, cat. no. CL3051; Cedarlane, Canada), and incubated for another 60 min at 37°C. The cells were then washed in DMEM (200 g, 5 min) and resuspended in WO 01/13947 PCT/SE00/01648 DMEM to a concentration of 1.4 x 105 cells/p.l. Anti-Gal-pretreated and controlpretreated cell suspensions contained 90% and 92% viable cells (trypan-blue negative), respectively.
In context herewith, it should be noted that the preceding paragraph is a preferred embodiment of the kit according to the invention.
Transplant recipients and induction of hemiparkinsonism. Twenty-two male Lewis rats weighing 230-340 g were anesthetized with Hypnorm (fentanyl citrate 0.20 mg/kg and fluanisone 6.3 mg/kg, Janssen, Belgium) and Dormicum (midazolam 4.2 mg/kg, Hoffmann-La Roche, Switzerland), and placed in a Kopf stereotaxic frame with the toothbar set at 3.9 mm below the interaural line. Unilateral lesions of the dopaminergic nigrostriatal pathways were produced by injecting 4.0 gl sterile saline containing 32 mM 6-hydroxydopamine HCI (Sigma) and 1.0% ascorbate at l/min at the following coordinates relative to bregma and dura mater: posterior 2.8 mm, right 2.0 mm, and ventral 8.4 mm. To relieve postoperative pain, Temgesic (buprenorphinum 0.10 mg/kg, Reckitt Colman, UK) was given upon completion of surgery. After 6 weeks, circling behavior of the animals in response to D-amphetamine sulphate (2.5 mg/kg, Sigma) was tested for 90 min in automated rotometer cylinders, as described (Ungerstedt et al., 1970), and 16 rats, all with more than 8 net turns per min ipsilateral to the lesion, were assigned to two groups (n 8) of equal rotational rates.
Intrastriatal transplantation. Seven weeks after injection of 6-hydroxydopamine, rats received 3.0 i1 DMEM with anti-Gal-pretreated or control-pretreated VM cells at dl/min at the following coordinates relative to bregma and dura mater: anterior 0.7 mm, right 2.6 mm, and ventral 4.7 mm (toothbar set at 2.5 mm below the interaural line). Animals were anesthetized and pain relieved as described above. Rotational response to D-amphetamine sulphate was assessed 3, 7, and 10 weeks posttransplantation, as described above, and Mann-Whitney statistical tests (p 0.03) WO 01/13947 PCT/SE00/01648 26 were performed for each time point (two-tailed p values were estimated using the z statistic).
Tissue processing and immunohistochemistry. All rats were sacrificed 10 weeks after transplantation by an overdose of pentobarbital and perfused transcardially with 4% paraformaldehyde in 0.15 M phosphate buffer (pH After perfusion, brains were immersed in the same fixative for 60 min, cryoprotected overnight in 20% sucrose in 0.15 M phosphate buffer (pH and frozen in gaseous CO 2 Four parallel series of cryostat sections were cut and mounted on gelatine-coated glass slides.
Whole series of sections were incubated for 30 min with 10% FCS in Tris-buffered saline (TBS, pH and then incubated overnight at 4 0 C with one of the following primary antibodies in TBS with 1% Triton X-100 (Sigma): mouse anti-cow IgGI (1:1000; clone DP.5.112; purchased from Dr. L. Soriano, France (soriag@aol.com)), polyclonal rabbit anti-rat tyrosine hydroxylase (1:250; Pel- Freez Biologicals, USA), or mouse anti-rat CD45 IgGi (1:100; clone MRC OX-1; Serotec, UK). The neurofilament and tyrosine-hydroxylase antibodies are known to crossreact with their respective porcine antigens, but the neurofilament antibody does not react with rodent neurofilament. Following rinsing for 3 x 15 min in TBS with 1% Triton X-100, the sections were incubated with biotinylated sheep anti-mouse Ig (1:200 in TBS with 1% Triton X-100; Amersham) or biotinylated donkey anti-rabbit Ig (1:200 in TBS with 1% Triton X-100; Amersham) for 60 min at 20 0 C, rinsed 3 x min in TBS with 1% Triton X-100, treated for 30 min with 0.06% H 2 0 2 in methanol to block endogenous peroxidase, rinsed 3 x 15 min in TBS with 1% Triton X-100, and incubated for 60 min with peroxidase-conjugated streptavidin (1:200 in TBS with FCS; DAKO). After a repeated rinse, 0.05% 3,3'-diaminobenzidine (Sigma) in TBS with 0.009% H202 was applied to the sections until a brown precipitate developed.
The sections were finally rinsed in distilled water, dehydrated in alcohol, cleared in xylene, and coverslipped in Depex mounting medium (BDH Laboratory, UK).
WO 01/13947 PCT/SE00/01648 27 Example 1 Macrophages/microglial cells become autofluorescent in culture, astrocvtes do not.
Unstained brain cells from 28-day-old pig fetuses were analysed with flow cytometry directly after isolation (Fresh) or after 14 days in primary culture (Cultured) (Fig. 1).
Plots A and B show the green and orange fluorescence of the cells. Histograms C and D show the frequency of cells as a function of their green fluorescence, and include identical markers (MI) and the percentage of the total cell number present within the markers. Plot B shows regions set to define autofluorescent (R1) and nonautofluorescent (R2) cell populations, and plots E and F show the size (forward scatter) and granularity (side scatter) of the autofluorescent (RI) and nonautofluorescent (R2) cells.
In flow cytometric analyses of unstained cells, freshly isolated porcine fetal brain cells came out as a single population of cells without autofluorescence, while primary cultures of these cells, prepared to favour growth of astrocytes and macrophages/ microglial cells, consisted of two cell populations: a larger population of nonautofluorescent cells and a smaller population of autofluorescent cells. The autofluorescent cells were more granular than the non-autofluorescent cells (Fig. 1).
Brain cells isolated from 28-day-old fetal pig brains were grown for 14 days in primary culture. Cells were immunostained using FITC-conjugated (green fluorescence) or RPE-conjugated (orange fluorescence) antibodies (Fig. The isotype control (IC) IgGi is the negative control for the CD 8 and CD56 stainings, and the isotype control IgG 2 a is the negative control for the CD44 and CD4 stainings. Cells were fixed and permeabilized prior to staining for GFAP. The GFAP control is a sample that received secondary antibody only. Regions were set in plots G and H to compare the GFAP staining of autofluorescent and non-autofluorescent cells. Mean green fluorescence intensity in arbitrary units: GRI 151, GR2 199, HRI 24, and HRZ 131. Similar results were obtained with cultured brain cells from fetal pigs.
WO 01/13947 PCT/SE00/01648 28 Only the autofluorescent cells were CD 18 positive, and only the non-autofluorescent cells were CD56 positive, while both populations were CD44 positive. Antibodies against CD4 only stained some of the autofluorescent cells, and only very faintly. The non-autofluorescent cells were stained more intensively by antibodies against the astrocyte marker glial fibrillary acidic protein (GFAP) than the autofluorescent cells (Fig. 2).
Cultured brain cells isolated from 28-day-old pig fetuses were incubated with fluorescein-labelled E. coli (Fig. The figure shows phagocytosis ofE. coli. Plot A shows cells from a culture that received fluorescein-labelled E. coli (green fluorescence) 30 min prior to flow cytometry, while plot B shows cells from an untreated culture. The confocal laser microscopy image shows a cross section of a cell stained with the lipophilic and fluorescent Dil prior to incubation with fluoresceinlabelled E. coli and dual-channel scanning. The red pseudocolour represents membranes and other lipids stained with Dil (rhodamine optical filter sets) and the yellow pseudocolour represents fluorescein-labelled E. coli (fluorescein optical filter sets). Scale bar: 10 pm. Flow cytometric analysis of brain-cell cultures incubated with fluorescein-labelled E. coli showed that the autofluorescent cell population split into two along the green-fluorescence axis of the dot plot, while the non-autofluorescent cell population remained as one (Fig. When examined in a fluorescence microscope, the green fluorescence of the bacteria was not associated with the plasma membrane (not shown). In cultures stained with the lipophilic and fluorescent Dil and subsequently incubated with fluorescein-labelled E. coli, confocal laser microscopy showed that the majority of the cells only were stained by Dil. Some cells had, however, fluorescent E. coli within cell borders (Fig. 3).
Porcine fetal brain cells, cultured under conditions that favour growth ofastrocytes and macrophages/microglial cells (Castellano et al., 1991), consisted of both autofluorescent cells and non-autofluorescent cells, when analysed by flow cytometry.
Autofluorescence is a known property of macrophages (Havenith et al., 1993; Nicod et WO 01/13947 PCT/SE00/01648 29 al., 1989), and might be due to endogenous flavoproteins (Aubin et al., 1979; Benson et al., 1979), which are excitable by the 488-nm lasers used in this study, and can emit light in the green and orange ranges of the spectrum. The autofluorescent cells had high granularity, again typical of macrophages. To determine whether the autofluorescent cells were macrophages, we stained the cultured cells with antibodies known to react with astrocytes or macrophages. and tested the cells for phagocytic activity. The autofluorescent cells were CD18'CD44'CD56-GFAP-, strongly suggesting that these cells indeed were macrophages or microglial cells. Since no marker was available to distinguish between macrophages and microglial cells, we refer to these cells as macrophages, as this is commonly done at this early stage of brain development (Perry et al., 1988). The non-autofluorescent cells were CD18- CD44'CD56+GFAP+, suggesting that these cells were astrocytes. After incubation of cultured brain cells with fluorescein-labelled E. coli, the autofluorescent cell population split into two along the green-fluorescence axis of the dot plot, and fluorescence microscopy and confocal laser microscopy revealed that the fluorescent bacteria were located within the cells, as strong evidence of phagocytic activity by the autofluorescent cells. Based on their phenotypic characteristics and phagocytic activity, we conclude that the autofluorescent cells were macrophages/microglial cells, while the non-autofluorescent cells were astrocytes.
Example 2 Macrophages/microglial cells induce proliferation of human T lymphocvtes. astrocytes do not Brain cells isolated from 28-day-old fetal pig brains were grown for 14 days in primary culture and flow sorted after staining with RPE-conjugated anti-CD56 (orange fluorescence) (Fig. A. Purity and viability. Cells were analysed by flow cytometry without further staining to determine the purity (region R1 was set to include the CD56-negative macrophages), and after staining with propidium iodide (orange fluorescence) to determine the viability. The numbers given are the percentages of cells within region R1. The viability of the astrocyte population was 91% (determined by trypan-blue exclusion). B. Ability to induce human T-cell proliferation. Allogeneic WO 01/13947 PCT/SE00/01648 mononuclear blood cells (MBC; H-8053), sorted astrocytes, and sorted macrophages were y-irradiated (50 Gy) to halt their proliferation and mixed with lymphocytes from either of two human individuals (H-3970 and H-3977) (3 wells per combination). As a negative control, the lymphocytes were incubated without stimulators (12 wells per combination). The proliferative activity was determined by 3 H]thymidine incorporation after 4 days of co-culture. Bars represent means and standard errors of means.
The proliferative activity of the lymphocytes was higher when co-cultured with sorted macrophages than when co-cultured with allogeneic mononuclear blood cells. In cocultures of sorted astrocytes and lymphocytes from either of the two human individuals, the proliferative activity was slightly higher in wells with lymphocytes and astrocytes than in wells with lymphocytes only, but the difference was only statistically significant for one of the individuals. An ANOVA was done for each individual: FH-3970 (df3,17) 139, p 3.8 x 10- 1 2 and FH-3977 (df 3,17) 216, p= 1.0 x 10'13. Stimulator cells were compared with medium in one-sided, unpaired t tests and all p values were less than 0.001, except when comparing the stimulatory ability of astrocytes and medium on lymphocytes from individual H-3977 (p 0.08).
By flow sorting, a highly enriched macrophage population (increase in macrophages from 7.6% to 91%) and a highly purified astrocyte population (more than 99% astrocytes) was obtained, and only a few percent of the sorted cells were dead. The sorted macrophages were strong inducers of human T-cell proliferation, even stronger than allogeneic mononuclear blood cells. The sorted astrocytes were only weak stimulators, and with one of the two human individuals, the T-cell proliferation was not significantly higher than the background proliferative activity.
WO 01/13947 PCT/SE00/01648 31 Example 3 The a-galactosvl epitope is expressed on macrophaees/microglial cells and not on neurons.
Pig embryonic VM cells, including neurons, glia, and endothelial cells were analysed by flow cytometry for expression of ao-galactosyl epitopes using biotinylated Bandereia Simplicifolia isolectin B4 (BS-IB4) (Fig. 5A). A slight shift in fluorescence of less than one log was noted for the bulkpopulation of brain cells when compared to the control. (FTTC-conjugated avidin alone). This should be compared to BS-IB4 staining of PLMECs where a shift to the right on the logarithmic scale of at least two ten log steps was seen (Fig. In order to verify these flow cytometry data, Western blot analysis was done on BS- IB4 reactive, solubilized glycoproteins isolated from cell membranes of VM, PLMEC and ECV cells following separation on 8% SDS-PAGE, in order to detect possible proteins carrying a-galactosyl epitopes. PLMECs were shown to express high levels of a-galactosyl epitopes (Fig. epitopes that were carried on several different protein backbones as indicated by staining of components with molecular weights ranging from high 220 kDa) to low 30 kDa) mass. Detection was accomplished by chemiluminescence and the two blots represent 5 and 10 second-exposures, respectively. Upon longer exposure times 10 seconds), we saw weak staining in the VM lane of a component of approximately 150 kDa size. Under these conditions, a component of similar size and staining intensity was seen among the ECV membrane proteins (Fig. 6).
The distribution of a-galactosyl epitopes on individual VM cell populations was examined using BS-IB4 immunohistochemistry. Fig. 7 shows a saggital section of the VM of a 27 day-old pig embryo stained immunohistochemically for tyrosine hydroxylase, which is the rate-limiting enzyme for dopamine production in dopaminergic neurons. Cell bodies and some axonal fibres are seen (Fig. 7A). Low power magnification of a coronal section of a 27 day-old pig embryo stained immunohistochemically using peroxidase-conjugated BS-IB4 isolectin (Fig. 7B).
WO 01/13947 PCT/SE00/01648 32 There is intense staining of embryonic brain microvascular endothelium (Fig. 7B), and a somewhat less intense staining of microglial cells/tissue resident macrophages as seen at higher magnification (Fig. 7C). No prominent staining was found on neurons or glial cells. Staining of cells similar in morphology to the BS-IB4 stained cells in panel C, was seen with a mouse mAb specific for monocytes/tissue macrophages, which also binds porcine microglial cells (Fig. 7D).
It is conceivable that the staining of VM membrane proteins, which was of approximately the same intensity as the staining of ECV proteins, may be due to recognition of determinants related to a-Gal. However, isolectin-histochemistry indicated that the majority of the a-Gal expression is restricted to endothelial cells and microglial cells/macrophages, and not to neurons and astrocytes, in fetal porcine brain tissue (Fig. BS-IB4 reactivity in the adult mouse brain has also been shown to be confined to capillaries (Peters et al., 1979). Therefore, a more-likely explanation for the low-level expression in the Western blot experiments, is that the a-Gal expressing cells constitute only a small fraction of the total number of cells in the VM.
Example 4 Purification of antibodies from human serum Human IgG, IgM, and anti-Gal were purified from serum pooled from more than healthy, blood type AB donors using beaded agarose with goat anti-human IgG (Fc specific; Sigma, USA), goat anti-human IgM (g-chain specific; Sigma), or porcine thyroglobulin (source of a-galactosyl epitope; Sigma), respectively. Five ml of slurry ml of packed beads) were poured into a column of 10 mm diameter and washed with PBS. Heat-inactivated human serum (40 ml) was applied at 0.5 ml/min using a peristaltic pump, the agarose was washed with several column volumes of PBS, and bound protein was eluted with 0.1 M glycine/HCl (pH=2.5) at 1.0 ml/min. Onemillilitre fractions were collected in tubes containing 0.1 ml neutralising buffer (1.5 M Tris/HC1, pH=8.8). The absorption at 280 nm was read spectrophotometrically, and contents of tubes containing protein were pooled, dialysed against 1% PBS, lyophilised, and resuspended in distilled water (1/100 of eluted volume). The protein WO 01/13947 PCT/SE00/01648 33 concentration was determined using a BCA Protein Assay Reagent Kit (Pierce, USA) according to the manufacturer's instructions.
The purity of the IgG and IgM preparations was analysed by SDS-PAGE: 4.0 gg of each sample was boiled in SDS reducing or non-reducing buffer for 5 min and loaded onto ready-made, 4-15% continuous gels (Bio-Rad, USA). After electrophoresis, the gels were stained using a silver-staining kit (Bio-Rad) according to the manufacturer's instructions. No IgM bands appeared in the IgG lanes, but weak IgG bands were present in the IgM lanes.
The a-galactosyl-epitope reactivity of the antibodies purified from human serum using porcine thyroglobulin was assessed by incubating 5.0x 105 Raji cells (human Burkitt lymphoma cell line) or Raji cells transfected and selected to stably express the porcine al,3-galactosyl transferase gene (Raji-GT cells) in 100 il PBS with or without 10 gg of the purified antibodies. After 60 min at 4°C, the cells were washed once in PBS 25 0 g, 5 min), incubated with rabbit anti-human IgG F(ab') 2 FITC (1:10; DAKO, Denmark) or rabbit anti-human IgM F(ab') 2 FITC (1:10; DAKO) at 4°C for 60 min, washed twice in PBS (250 g, 5 min), and analysed by flow cytometry. The expression of the a-galactosyl epitope on Raji-GT cells was verified by staining Raji-GT cells and Raji cells with 3.0 pg FITC-conjugated BS-IB4. Transfection and selection of the Raji-GT cell line has been described by Kumagai-Braesch et al. (1998).
Example 5 Macrophages/microglial cells cultured from embryonic pig brain tissue express the a-galactosvl epitope Porcine embryonic brain cells were grown in primary culture with a high serum content in the medium, conditions which produce autofluorescent macrophages/ microglial cells and non-autofluorescent astrocytes, as shown in Example 1.
WO 01/13947 PCT/SE00/01648 34 Cultured cells were analysed unstained and after staining with FITC-conjugated Bandereia Simplicifolia isolectin B4 (BS-IB4 FITC) by flow cytometry. The dotplots show the intensity of green (FL1) and orange (FL2) fluorescence (see Fig. and contain a line that separates autofluorescent macrophagesimicroglial cells from non-autofluorescent astrocytes Staining resulted in an increase in greenfluorescence geometric means of 1167 units for macrophages/microglial cells and 16 units for astrocytes. Thus, macrophages/microglial cells express the a-galactosyl epitope, but it is not clear whether the weak staining of astrocytes reflects low agalactosyl-epitope expression or unspecific binding of BS-IB4 FITC. Note the logarithmic scales on the axes. The photomicrograph (300x) shows adherent, cultured brain cells which were fixed, permeabilized, and stained with biotinylated BS-IB4 and peroxidase-conjugated streptavidine. The BS-IB4-positive cells are rounded with the DAB staining product concentrated on the cell membrane.
As shown by McKenzie et al., 1995, the a-galactosyl epitope expression may change when porcine tissue is cultured, but macrophages/microglial cells from embryonic pig brain maintained their a-galactosyl epitope expression in culture (Fig. 8).
Example 6 Human serum and rabbit complement remove macrophages/microglial cells from cultured and freshly isolated porcine embryonic brain cells Dissociated brain tissue was split into aliquots, of which one was treated with human serum and rabbit complement prior to culture for 10 days, and another received an identical treatment after culture. These cells and untreated, cultured cells were analysed by flow cytometry without prior staining to compare the content of macrophages/microglial cells. In Fig. 9, the histograms show the cell frequency as a function of green-fluorescence intensity (FL and contain identical markers (M1) to define the autofluorescent macrophages/microglial cells and the percentage of the cells that are within the markers. Both when applied to freshly isolated cells and to cells grown in primary culture, treatment with human serum and rabbit complement reduced the relative number of macrophages/microglial cells.
WO 01/13947 PCT/SE00/01648 Example 7 Treatment of porcine brain cells with anti-Gal and complement reduces the content of macrophages/microglial cells and their ability to induce human CD4 Tlymphocyte proliferation Raji cells (Raji) and Raji cells transfected to express porcine al,3-galactosyltransferase (and thus the a-galactosyl epitope; Raji-GT) were incubated with the antibodies against the a-galactbsyl epitope (purified from normal serum as described in Example 4; in Fig. 10 referred to as aGal) or no antibodies and stained with either FITC-conjugated anti-human IgG (aIgG) or FITC-conjugated anti-human IgM (algM).
The expression of the a-galactosyl epitope on Raji-GT cells was verified by staining these and Raji cells with FITC-conjugated BS-IB4. The purified antibodies contained both IgG and IgM reactive with Raji-GT cells, but not with Raji cells. Unspecific staining of Raji-GT cells by aIgG and algM was minimal, and the purified antibodies thus contained both IgG and IgM reactive with the a-galactosyl epitope (see Fig. Porcine embryonic brain cells were grown in primary culture for 12 days, dissociated, and incubated with human IgG (circle in Fig. 11), human IgM (square in Fig. 11), human anti-Gal (triangle in Fig. 11), human serum (diamond in Fig. 11), or medium (filled circle in Fig. 11). Human IgG, IgM and anti-Gal were prepared as described in Example 4. After 60 min at 4°C, the cells were washed, resuspended in medium with rabbit complement, incubated at 37 0 C for 60 min, washed again, y-irradiated to halt their proliferation, and mixed with highly purified human peripheral blood CD4 T cells. CD4 T cells were also grown in absence of brain cells to determine their background proliferative activity (cross in Fig. 11). Proliferation was determined as incorporation of tritiated thymidine, and means of triplicate cultures are given in counts per minute (cpm) in Fig. 11. Bars represent one SEM. IgG and IgM reactive with the a-galactosyl epitope were present in the anti-Gal preparation (Fig. 10). The effect of the different brain-cell pretreatments on the content of macrophages/ microglial cells and cell viability is given in Table 1 below.
WO 01/13947 PCT/SE00/01648 36 Table 1. Content of macrophages/microglial cells and cell viability of pretreated porcine embryonic brain cells for co-culture with human CD4 T lymphocytes Pretreatment Macrophages/microglial cells Viable cells Human IgG 1.4 83.2 Human IgM 1.1 87.5 Human anti-Gal 0.8 87.1 Human serum 1.1 89.6 Medium 3.4 87.5 Cultured porcine embryonic brain cells treated with human IgG, human IgM, human anti-Gal, or human serum and rabbit complement did not induce proliferation of human CD4 T cells, while brain cells given a control treatment with medium and rabbit complement induced a significant proliferative response in human CD4 T cells (Fig. 11).
Even though human IgG, human IgM, human anti-Gal, and human serum were not equally effective at removing macrophages/microglial cells (Table the proliferative response of the CD4 T cells to the remaining brain cells was not higher than background activity (Fig. 11). This suggests the presence of a threshold, below which the macrophages/microglial cells are too few to elicit a T-cell response in vitro, and possibly in vivo.
An in-vitro model was used to study the human CD4 T-cell response to porcine embryonic brain cells (Fig. 12). The brain cells were grown in primary culture prior to co-culture with human CD4 T cells, because only cultured cells, and not freshly isolated cells, will induce proliferation of human T cells (Brevig et al., 1997).
Culturing under the conditions described herein, like intracerebral transplantation (Mason et al., 1986; Duan et al., 1995), upregulates the expression of MHC antigens (Brevig et al., 1999).
WO 01/13947 PCT/SE00/01648 37 Fig. 12 shows a summary of the effect of anti-Gal and complement on dissociated porcine brain tissue in the clinical situation and in the in-vitro model used by the inventors. Dissociated brain tissue from pig embryos contains neurons astrocytes macrophages/microglial cells and endothelial cells The latter two cell types express the a-galactosyl epitope (c-Gal), and their removal prior to transplantation will greatly reduce the potential of the donor tissue to upregulate MHC antigens, particularly class II, once implanted. Primary culture in medium with a high serum content favours growth of astrocytes and macrophages, and upregulates the expression of MHC antigens. Dissociated porcine brain tissue cultured under these conditions can thus be used to study the human T-cell response to porcine neural xenoerafts in vitro.
The approach of the inventors, which is shown in Figure 12, was to target the agalactosyl epitope, because it is expressed on macrophages/microglial cells, but not on neurons, in fresh porcine brain tissue (Sumitran et al., 1999), and (ii) to use antibodyand complement-mediated lysis, since even macrophages/microglial cells within small cell clusters can be removed by this mechanism.
Pretreatment of dissociated porcine brain tissue with anti-Gal and complement probably also removes endothelial cells, because the a-galactosyl epitope is abundantly expressed on endothelial cells in embryonic pig brain (Sumitran et al., 1999), and porcine aortic endothelial cells are sensitive to lysis by anti-Gal and complement (Vaughan et al., 1994). In culture, porcine aortic endothelial cells constitutively express class I, but not class II, MHC antigens, and induce proliferation of human CD8, but not CD4, T cells (Murray et al., 1994). After culture with human tumour necrosis factor-o, which may be present in neural grafts due to surgically induced inflammation, porcine aortic endothelial cells also express MHC class II antigens and induce proliferation of human CD4 T cells (Batten et al., 1996). Removal of endothelial cells may thus be beneficial for the survival of neural xenografts, but it is not known whether donor-derived endothelial cells are necessary for xenograft neovascularization in humans. However, in an allogeneic rat model, whole-suspension WO 01/13947 PCT/SE00/01648 38 grafts and grafts depleted of microglial cells and endothelial cells developed identically in terms of neovascularization and colonisation by host microglial cells (Pennell and Streit, 1997).
Example 8 Effects of the pretreatment on survival and function of porcine neural xenografts in rats Immunocompetent rats with 6 -hydroxydopamine-induced hemiparkinsonism received dissociated VM tissue pretreated with anti-Gal and complement or medium and complement (control), and the functional effects of the grafts were followed over time until sacrifice of the animals at 10 weeks posttransplantation (Fig. 13). In 5 of 8 rats receiving VM cells pretreated with anti-Gal and complement, a reduction of amphetamine-induced circling behavior by more than 50% occurred during the week follow-up. *The lesion in this recipient progressed beyond the time of transplantation. tLarge graft with several clusters of dopaminergic neurons (photomicrographs shown in Fig. 14). ISmall graft with few dopaminergic neurons.
None of the 8 rats receiving control-pretreated VM cells displayed this degree of improvement. Histological analysis revealed a small graft, densely infiltrated by macrophages and containing only a few dopaminergic neurons, in one animal in the control group (not shown), and a large graft containing several clusters of dopaminergic neurons in one animal receiving VM cells pretreated with anti-Gal and complement (Fig. 14). The rest of the animals had completely rejected their grafts. (A) Shows an even distribution of porcine neurofilament in the graft. Section stained for tyrosine hydroxylase, a marker for dopaminergic neurons, with stained cell bodies clustered and located at the graft-host interface, which is common for intrastriatal grafts of dissociated VM tissue. Dopaminergic cell bodies at high magnification (arrows). Shows infiltration by host leukocytes (staining for CD45) around a vessel at the graft-host interface (arrow). Gr, graft. Str, host striatum. Scale bars: 250 pmn (A and B) and 25 pim (C and D).
WO 01/13947 PCT/SE00/01648 39 Previous studies disagree as to whether non-pretreated porcine embryonic VM grafts induce behavioral effects in hemiparkinsonian, immunocompetent rats (Barker et al.
2000; Larsson et al., 2000; Galpern et al., 1996), emphasizing the importance of using identical aliquots of donor material for testing donor-tissue pretreatments. Functional benefit from the grafts pretreated with anti-Gal and complement was observed 7 weeks posttransplantation, which is consistent with other studies (Barker et al., 2000; Larsson et al., 2000; Galpern et al., 1996; Huffaker et al., 1989), in which functional benefit from non-pretreated porcine embryonic VM grafts occurred after 7-9 weeks in immunosuppressed rats.
Two studies have previously attempted to reduce the immunogenicity of brain tissue.
Bartlett et al. upregulated MHC antigens on murine embryonic neural cells by culture with interferon y, and showed that depletion of MHC class-I positive cells by flow sorting improves graft survival in brains of allogeneic mice (Bartlett et al., 1990). As a pretreatment of dissociated porcine embryonic brain tissue, Pakzaban et al. masked MHC class I antigens by divalent antigen-binding fragments of antibodies, and found improved graft survival in rat brain (Pakzaban et al., 1995). Masking MHC class I antigens on porcine embryonic brain cells reduces the proliferative response of human CD8 T cells by about 50% in vitro (DerSimonian et al., 1999). MHC antigens are, however, not optimal targets for donor tissue pretreatments, because these molecules are present at very low levels in fresh brain tissue (Lampson, 1995) and upregulated after implantation (Widner et al., 1988; Duan et al., 1995; Mason et al., 1986) (Fig.
12).
We conclude that pretreatment with anti-Gal and complement reduces the immunogenicity of porcine neural tissue. In order to estimate what can be expected from this pretreatment in the clinical situation, it will be necessary to transplant pretreated porcine neural tissue into the brains of Old-World monkeys, because these primates can be expected to have cellular and humoral immune responses comparable with those in humans, particularly the contribution of direct and indirect T-cell responses to the rejection of porcine grafts (Brevig et al., 2000). The pretreatment with WO 01/13947 PCT/SE00/01648 anti-Gal and complement might be a valuable alternative or supplement to immunosuppression, and it can, unlike current immunosuppressive drugs, be expected to have no side effects. Moreover, like immunosuppression, it can be combined with other strategies to reduce cellular immune rejection, for example, MHC class-I masking (Pakzaban et al., 1995) and Sertoli-cell co-grafting (Sanberg et al., 1996). and with strategies to reduce the complement response (Cozzi et al., 1995).
References Aubin J E (1979) Autofluorescence of viable cultured mammalian cells. J. Histochem.
Cvtochem. 27: 36-43.
Auchincloss H, Sachs D H (1998) Xenogeneic transplantation. Annu Rev Immunol 16:433-470.
Barker R A, Fricker R A, Abrous D N, Fawcett J, Dunnett S B (1995) A comparative study of preparation techniques for improving the viability of nigral grafts using vital stains, in vitro cultures, and in vivo grafts. Cell Transplantation, Mar-Apr; 4(2):173-200.
Barker R A, Ratcliffe E, Mclaughlin M, Richards A, Dunnett S B (2000) J. Neurosci.
20:3415-3424.
Bartlett P F, Rosenfeld J, Bailey K A, Cheesman H,.Harvey A R, Kerr R S (1990) Allograft rejection overcome by immunoselection of neuronal precursor cells. Prog Brain Res 82:153-160.
Batten P, Yacoub M H, Rose M L (1996) Effect of human cytokines (IFN-y, TNF-a, IL-13, IL-4) on porcine endothelial cells: induction of MHC and adhesion molecules and functional significance of these changes. Immunology 87:127-133.
Benson R C, Meyer R A, Zaruba M E, McKhann G M (1979) Cellular autofluorescence is it due to flavins? J. Histochem. Cytochem. 27: 44-48.
Borlongan C V, Stahl C E, Cameron D F, Saporta S, Freeman T B, Cahill D W, Sanberg P R (1996) CNS immunological modulation of neural graft rejection and survival. Neurol Res 18:297-304.
WO 01/13947 PCT/SE00/01648 41 Borlongan C V, Sanberg P R, Freeman T B (1999) Neural transplantation for neurodegenerative disorders. Lancet 353 Suppl 1:29-30.
Brevig T, Pedersen E B, Kristensen T, Zimmer J (1997) Proliferative response of human T lymphocytes to porcine fetal brain cells. Cell Transplant 6:571-577.
Brevig T, Kristensen T, Zimmer J (1999) Expression of major histocompatibility complex antigens and induction of human T-lymphocyte proliferation by astrocytes and macrophages from porcine fetal brain. Exp Neurol 159:474-483.
Brevig T, Holgersson J, Widner H (2000) Trends Neurosci. (in press).
Castellano B, Gonzalez B, Jensen M B, Pedersen E B, Finsen B R, Zimmer J (1991) A double staining technique for simultaneous demonstration of astrocytes and microglia in brain sections and astroglial cell cultures. J. Histochem. Cytochem. 39: 561-568.
Cozzi E, White D J (1995) The generation of transgenic pigs as potential organ donors for humans. Nature Med 1:964-966.
Deacon T, Schumacher J, Dinsmore J, Thomas C, Palmer P, Kott S, Edge A, Penney D, Kassissieh S, Dempsey P, Isacson O (1997) Histological evidence of fetal pig neural cell survival after transplantation into a patient with Parkinson's disease.
Nature Med 3:350-353.
DerSimonian H, Pan L, Yatko C, Rodrigue-Way A, Johnson E, Edge A S B (1999) J.
Immunol. 162:6993-7001.
Dorling A, Lombardi G, Binns R, Lechler R I (1996) Detection of primary direct and indirect human anti-porcine T cell responses using a porcine dendritic cell population. Eur J Immunol 26:1378-1387.
Duan W-M, Widner H, Brundin P (1995) Temporal pattern of host responses against intrastriatal grafts of syngeneic, allogeneic or xenogeneic embryonic neuronal tissue in rats. Exp Brain Res 104:227-242.
Dunnett S B, Bjorklund A (1999) Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 399 Suppl:A32-A39.
Edge A S, Gosse M E, Dinsmore J (1998) Xenogeneic cell therapy: current progress and future developments in porcine cell transplantation. Cell Transplant 7:525-539.
WO 01/13947 PCT/SE00/01648 42 Galili U (1993) Interaction of the natural anti-Gal antibody with ao-galactosyl epitopes: a major obstacle for xenotransplantation in humans. Immunol Today 14:480-482.
Galpern W R, Bums L H, Deacon T W, Dinsmore J, Isacson O (1996) Xenotransplantation of porcine fetal ventral mesencephalon in a rat model of Parkinson's disease: functional recovery and graft morphology. Exp Neurol 140:1- 13.
Gill R G, Wolf L (1995) Immunobiology of cellular transplantation. Cell Transplant 4:361-370.
Grabowska A, Lampson L A (1992) Expression of class I and II major histocompatibility complex (MHC) antigens in the developing CNS. J Neural Transplant Plast 3:204-205.
Grasbon-Frodl E M, Nakao N, Brundin P (1996) The lazaroid U-83836E improves the survival of rat embryonic mesencephalic tissue stored at 4 degrees C and subsequently used for cultures or intracerebral transplantation. Brain Res. Bull. 39: 341-347.
Hallberg E C, Holgersson J, Samuelsson B E (1998) Glycosphingolipid expression in pig aorta. Identification of possible target antigens for human natural antibodies.
Glycobiology 8, 637-649.
Havenith C E, A J Breedijk, M P van, N Blijleven, W Calame, R H Beelen, E C Hoefsmit (1993) Separation of alveolar macrophages and dendritic cells via autofluorescence: phenotypical and functional characterization. J. Leukoc. Biol. 53: 504-510.
Huffaker T K, Boss B D, Morgan A S, Neff N T, Strecker R E, Spence M S, Miao R (1989) Xenografting of fetal pig ventral mesencephalon corrects motor asymmetry in the rat model of Parkinson's disease. Exp Brain Res 77:329-336.
Isacson O, Breakefield X O (1997) Benefits and risks of hosting animal cells in the human brain. Nature Med 3:964-969.
Isacson O, Deacon T W, Pakzaban P, Galper W R, Dinsmore J, Burs L H (1995) Transplanted xenogeneic neural cells in neurodegenerative disease models exhibit remarkable axonal target specificity and distinct growth patterns of glial and axonal fibres. Nature Med 1:1189-1194.
WO 01/13947 PCT/SE00/01648 43 Jacobs D, Pipho C (1983) Use of propidium iodide staining and flow cytometry to measure antibody-mediated cytotoxicity: resolution of complement-sensitive and resistant target cells. J. Immunol. Meth. 62: 101-108.
Kaufman C L, Gaines B A, lldstad S T (1995) Xenotransplantation. Annu Rev Immunol 13:339-367.
Kirk A D, Li R A, Kinch M S, Abernethy K A, Doyle C, Bollinger R R (1993) The human antiporcine cellular repertoire. In vitro studies of acquired and innate cellular responsiveness. Transplantation 55:924-931.
Kohler and Milstein (1975) Nature 256: 495-497.
Korsgren O (1997) Acute cellular xenograft rejection. Xenotransplantation 4:11-19.
Kumagai-Braesch M, Satake M, Korsgren O, Andersson A, Miller E (1993) Characterization of cellular human anti-porcine xenoreacrivity. Clin Transplant 7:273-280.
Kumagai-Braesch M, Satake M, Qian Y, Holgersson J, Moiler E (1998) Human NK cell and ADCC reactivity against xenogeneic porcine target cells including fetal porcine islet cells. Xenotransplantation 5:132-145.
Laemmli U K (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
Lampson L A (1995) Interpreting MHC class I expression and class I/class II reciprocity in the CNS: reconciling divergent findings. Microsc Res Tech 32:267- 285.
Larsson L C, Czech K A, Brundin P, Widner H (2000) Cell Transplant. 9:261-272.
Liu J, Qian Y, Holgersson J (1997) Removal of xenoreactive human anti-pig antibodies by absorption on recombinant mucin-containing glycoproteins carrying the Gall 1,3Gal epitope. Transplantation 63, 1673-1682.
Mason D W, Charlton H M, Jones A J, Lavy C B, Puklavec M, Simmonds S J (1986) The fate of allogeneic and xenogeneic neuronal tissue transplanted into the third ventricle of rodents. Neuroscience 19:685-694.
McKenzie I F C. Koulmanda M, Mandel T E, Xing P-X, Sandrin M S (1995) Pig-tohuman xenotransplantation: the expression of Gala(l-3)Gal epitopes on pig islet cells. Xenotransplantation 2:1-7.
WO 01/13947 PCT/SE00/01648 44 Murray A G, Khodadoust M M, Pober J S, Bothwell A L (1994) Porcine aortic endothelial cells activate human T cells: direct presentation of MHC antigens and costimulation by ligands for human CD2 and CD28. Immunity 1:57-63.
Nakao N, Frodl E M, Duan W M, Widner H, Brundin P (1994) Lazaroids improve the survival of grafted rat embryonic dopamine neurons. Proc. Natl. Acad. Sci. USA 91:12408-12412.
Nicod L P, Lipscomb M F, Toews G B, Weissler J C (1989) Separation of potent and poorly functional human lung accessory cells based on autofluorescence. J. Leukoc.
Biol. 45: 458-465.
Okura Y, Tanaka R, Ono K, Yoshida S, Tanuma N, Matsumoto Y (1997) Treatment of rat hemiparkinson model with xenogeneic neural transplantation: tolerance induction by anti-T-cell antibodies. J Neurosci Res 48:385-396.
Olanow C W, Freeman T B, Kordower J H (1997) Neural transplantation as a therapy for Parkinson's disease. Adv Neurol 74:249-269.
Pakzaban P, Deacon T W, Burns L H, Dinsmore J, Isacson O (1995) A novel mode of immunoprotection of neural xenotransplants: masking of donor major histocompatibility complex class I enhances transplant survival in the central nervous system. Neuroscience 65:983-996.
Pennell N A, Streit W J (1997) Colonization of neural allografts by host microglial cells: relationship to graft neovascularization. Cell Transplant 6:221-230.
Perry V H, Gordon S (1988) Macrophages and microglia in the nervous system.
Trends. Neurosci. 11:273-277.
Peschanski M, Cesaro P, Hantraye P (1995) Rationale for intrastriatal grafting of striatal neuroblasts in patients with Huntington's disease. Neuroscience 68:273-285.
Peters B P, Goldstein I J (1979) The use of fluorescein-conjugated Bandereia simplicifolia B4-isolectin as a histochemical reagent for the detection of a-Dgalactopyranosyl groups. Exp. Cell Res. 120:321-334.
Pierson R N, Winn H J, Russell P S, Auchincloss H (1989) Xenogeneic skin graft rejection is especially dependent on CD4+ T cells. J Exp Med 170:991-996.
Rother R P, Squinto S P (1996) The a-galactosyl epitope: a sugar coating that makes viruses and cells unpalatable. Cell 86:185-188.
WO 01/13947 PCT/SE00/01648 Sanberg P R, Borlongan C V, Saporta S, Cameron D F (1996) Nat. Biotechnol.
14:1692-1695.
Satake M, Korsgren O, Ridderstad A, Karlsson P A, Wallgren A C, M611er E (1994) Immunological characteristics of islet cell xenotransplantation in humans and rodents. Immunol Rev 141:191-211.
Sumitran S, Liu J, Czech K A, Christensson B, Widner H, Holgersson J (1999) Human natural antibodies cytotoxic to pig embryonic brain cells recognize novel non- Galal,3Gal-based xenoantigens. Exp Neurol 159:347-361.
Ungerstedt U, Arbuthnott G W (1970) Brain Res. 24, 485-493.
Vaughan H A, Loveland B E, Sandrin M S (1994) Gala(1,3)Gal is the major xenoepitope expressed on pig endothelial cells recognized by naturally occurring cytotoxic human antibodies. Transplantation 58:879-882.
Watts C, Caldwell M A, Dunnett S B (1998) The development of intracerebral cellsuspension implants is influenced by the grafting medium. Cell Transplantation, Nov-Dec;7(6):573-83.
Wennberg L, Wallgren A C, Sundberg B, Rafael E, Zhu S, Tibell A, Karlsson P A, Groth C G, Korsgren O (1995) Efficacy ofimmunosuppressive drugs in islet xenotransplantation: a study in the pig-to-rat model. Xenotransplantation 2:222-229.
Widner H, Brundin, P (1988) Brain Res. Rev. 472: 287-324.
Wood M J, Sloan D J, Wood K J. Charlton H M (19.96) Indefinite survival of neural xenografts induced with anti-CD4 monoclonal antibodies. Neuroscience 70:775- 789.
Yamada K, Sachs D H, DerSimonian H (1995) Human anti-porcine xenogeneic T cell response. Evidence for allelic specificity of mixed leukocyte reaction and for both direct and indirect pathways of recognition. J Immunol 155:5249-5256.
Zawada W M, Cibelli J B, Choi P K, Clarkson E D, Golueke P J, Witta S E, Bell K P, Kane J, Ponce-de L F, Jerry D J, Robl J M, Freed C R, Stice S L (1998) Somatic cell cloned transgenic bovine neurons for transplantation in parkinsonian rats.
Nature Med 4:569-574.
Claims (14)
1. Transplantation material, which has been produced by dissociation of porcine embryonic or fetal neural tissue; and removal of macrophages and/or microglial cells by exposing the preparation of step to antibodies against the Galal-3Galpl-R epitope and a complement reagent.
2. Transplantation material according to claim 1, wherein the dissociation is effected by the use of one or more enzymes.
3. Transplantation material according to claim 2, wherein the enzymes are proteases and/or deoxyribonucleases.
4. Transplantation material according to any one of claims 1-3, wherein the complement reagent is rabbit serum or complement purified from rabbit serum.
Use of a transplantation material according to any one of claims 1-4, for preparing a pharmaceutical :.preparation which is useful when transplanting neural 25 tissue.
6. A kit used for treating a porcine tissue in order to reduce its immunogenicity comprising an antibody against macrophages and/or microglial cells, and one or more enzymes for tissue dissociation and a complement reagent. o*
7. A kit according to claim 6, wherein the enzymes are proteases and/or deoxyribonucleases. H:\mcamp\keep\retype\P44899 Amended Pages Claims AbSorber.doc 14/05/04 47
8. A process for removal of macrophages and/or microglial cells from porcine embryonic or fetal neural tissue, comprising the steps of: dissociating neural tissue and treating with an antibody against the Galal-3-Gall-R epitope; and depleting the macrophages and/or microglial cells from the preparation of step by exposing the preparation in step to the antibody coupled to a carrier or by flow sorting; or depleting the macrophages and/or microglial cells from the preparation of step by treating the preparation of step with a complement reagent.
9. A process according to claim 8, wherein the porcine embryonic or fetal neural tissue is dissociated by the use of one or more enzymes; the antibody is a polyclonal antibody, against the Galal-3Galpl-R epitope; the complement reagent is rabbit serum or complement purified from rabbit serum.
A process according to claim 9, wherein the antibody is of human origin.
:11. A process according to claim 9, wherein the enzymes are proteases and/or deoxyribonucleases.
12. A process for treatment of neurological disorders comprising the steps of: a) dissociating porcine embryonic or fetal neural tissue; b) treating the dissociated tissue with antibodies against the Galal-3Galpl-R epitope and a 35 complement reagent in order to remove macrophages and/or microglial cells; and H:\mcamp\keep\retype\P44899 Amended Pages Claims AbSorber.doc 14/05/04 48 c) transplanting the dissociated and antibody- and complement-treated tissue into the human body.
13. A process according to claim 12, wherein the neurological disorder is selected from the group consisting of Parkinson's disease, Huntington's disease, multiple sclerosis, epilepsy, stroke, pain, and spinal cord injuries.
14. Use of transplantation material according to claim 1 in the treatment of a neurological disorder. Transplantation material according to claim 1 substantially as hereinbefore described with reference to anyone of the Examples. Dated this 14 th day of May 2004 ABSORBER AB By their Patent Attorneys GRIFFITH HACK Fellows Institute of Patent and Trade Mark Attorneys of Australia *I .in 9v Co oC H:\mcamp\keep\retype\P44899 Amended Pages Claims AbSorber.doc 14/05/04
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9903021A SE9903021D0 (en) | 1999-08-26 | 1999-08-26 | Reduction of the immunogenicity of non-human grafts |
SE9903021 | 1999-08-26 | ||
PCT/SE2000/001648 WO2001013947A1 (en) | 1999-08-26 | 2000-08-28 | Reduction of the immunogenicity of non-human grafts |
Publications (2)
Publication Number | Publication Date |
---|---|
AU7046000A AU7046000A (en) | 2001-03-19 |
AU774651B2 true AU774651B2 (en) | 2004-07-01 |
Family
ID=20416763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU70460/00A Ceased AU774651B2 (en) | 1999-08-26 | 2000-08-28 | Reduction of the immunogenicity of non-human grafts |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1207903A1 (en) |
JP (1) | JP2003507131A (en) |
AU (1) | AU774651B2 (en) |
SE (1) | SE9903021D0 (en) |
WO (1) | WO2001013947A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060147429A1 (en) * | 2004-12-30 | 2006-07-06 | Paul Diamond | Facilitated cellular reconstitution of organs and tissues |
EP3401682A1 (en) * | 2017-05-09 | 2018-11-14 | Université de Nantes | Diagnosis, prevention and treatment of demyelinating disorders of the central nervous system |
CN109187958A (en) * | 2018-09-12 | 2019-01-11 | 福建中医药大学附属人民医院(福建省人民医院) | A kind of rat CD4 antibody coating magnetic bead and its preparation method and application and the kit containing the magnetic bead |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2221234A1 (en) * | 1995-05-15 | 1996-11-21 | Cedars-Sinai Medical Center | Compositions and methods for inhibiting xenograft rejection |
US6610288B1 (en) * | 1995-05-26 | 2003-08-26 | Diacrin, Inc. | Porcine hepatocytes for use in treatment of disorders characterized by insufficient liver function |
-
1999
- 1999-08-26 SE SE9903021A patent/SE9903021D0/en unknown
-
2000
- 2000-08-28 WO PCT/SE2000/001648 patent/WO2001013947A1/en not_active Application Discontinuation
- 2000-08-28 EP EP00959076A patent/EP1207903A1/en not_active Withdrawn
- 2000-08-28 JP JP2001518083A patent/JP2003507131A/en active Pending
- 2000-08-28 AU AU70460/00A patent/AU774651B2/en not_active Ceased
Non-Patent Citations (1)
Title |
---|
J. IMMUNOL. METH., VOL. 222, 1999 PP31-44 * |
Also Published As
Publication number | Publication date |
---|---|
EP1207903A1 (en) | 2002-05-29 |
JP2003507131A (en) | 2003-02-25 |
WO2001013947A1 (en) | 2001-03-01 |
SE9903021D0 (en) | 1999-08-26 |
AU7046000A (en) | 2001-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WALLGREN et al. | THE MAIN INFILTRATING CELL IN XENOGRAFT REJECTION IS A CD4+ MACROPHAGE AND NOT AT LYMPHOCYTE | |
EP2088864B1 (en) | Selective immunodepletion of endogenous stem cell niche for engraftment | |
CN1454215B (en) | Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby | |
DE60026166T2 (en) | VETOCELLS THAT ARE EFFECTIVE IN PREVENTING TRANSPLANT DISCHARGE AND HAVING NO GRAFT VERSUS HOST POTENTIAL | |
JP2003531578A (en) | Methods and compositions for producing human monoclonal antibodies | |
US20010053362A1 (en) | Applications of immune system tolerance to treatment of various diseases | |
WO2003039232A2 (en) | Endothelial cell derived hemotopoietic growth factor | |
Sheikh et al. | Alpha-gal-independent dual recognition and activation of xenogeneic endothelial cells and human naive natural killer cells1 | |
EP2595637B1 (en) | Regulatory immune cells with enhanced targeted cell death effect | |
Wen et al. | Allo‐skin graft rejection, tumor rejection and natural killer activity in mice lacking p56lck | |
CA2571272A1 (en) | Anti-lympho- plus anti-monocytes globulin preparation for inhibiting immune responses | |
Sumitran et al. | Human natural antibodies cytotoxic to pig embryonic brain cells recognize novel non-Galα1, 3Gal-based xenoantigens | |
AU665042B2 (en) | Suppressor and progenitor cells | |
Schneider et al. | Pluripotent hemopoietic stem cells give rise to osteoclasts | |
AU774651B2 (en) | Reduction of the immunogenicity of non-human grafts | |
Brevig et al. | XENOTRANSPLANTATION FOR BRAIN REPAIR: Reduction of Porcine Donor Tissue Immunogenicity by Treatment with Anti-Gal Antibodies and Complement: 1 | |
JP2001139496A (en) | Method for acquiring acquired tolerance | |
Brevig et al. | Expression of major histocompatibility complex antigens and induction of human T-lymphocyte proliferation by astrocytes and macrophages from porcine fetal brain | |
AU5699599A (en) | Cells expressing immunoregulatory molecules and uses therefor | |
US6953576B2 (en) | Method of modulating tumor immunity | |
CN113347991A (en) | Combination of compositions for eliminating and enhancing hematopoietic stem cell engraftment in bone marrow of a subject | |
KR100666607B1 (en) | METHOD OF PRODUCING Xenogenic CD4 T-CELL AND ANIMAL MODEL PRODUCING Xenogenic CD4 T-CELL | |
KR20060035640A (en) | Method for transplanting lymphohematopoietic cells into mammal | |
JP2647292B2 (en) | Non-human chimeric mammal | |
JP2001512423A (en) | Tolerance to natural antibody antigens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |